PKIDB: A Curated, Annotated and Updated Database of Protein Kinase Inhibitors in Clinical Trials

How to cite PKIDB:

Carles, F., Bourg, S., Meyer, C., and Bonnet, P. (2018). PKIDB: A Curated, Annotated and Updated Database of Protein Kinase Inhibitors in Clinical Trials. Molecules 23, 908. DOI:10.3390/molecules23040908
Bournez, C., Carles, F., Peyrat, G., Aci-Sèche, S., Bourg, S., Meyer, C. and Bonnet, P. (2020). Comparative Assessment of Protein Kinase Inhibitors in Public Databases and in PKIDB. Molecules 25, 3226. DOI:10.3390/molecules25143226

Acknowledgements:

To KLIFS from Vrije Universiteit Amsterdam to link our data on their database.

Latest update: 2023-01-16

Last approved inhibitors:

New inhibitors this month: Emprumapimod, Ivarmacitinib, Pirotinib

Links to KinoMine data: Bioactivities, 3D structures and binding mode

Download sdf file: pkidb_2023-01-16.sdf

INN_Name	BrandName	Phase	Applicants	Links	LigID	pdbID	Type	RoF	MW	LogP	TPSA	HBA	HBD	NRB	Indications	Targets	Kinase families	Canonical_Smiles	InChiKey	First_Approval	SC_Patent	Chirality	Synonyms	FDA_approved	Melting point
Dezapelisib		0	Incyte Corporation	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	0	421.1	3.7	100.9	8	2	4	nan	nan		Cc1csc2n1c(=O)c(c(n2)[C@H](C)Nc3c4c([nH]cn4)ncn3)c5cccc(c5)F	RSIWALKZYXPAGW-NSHDSACASA-N	nan	None	Single Stereoisomer	DEZAPELISIB INCB040093
Oclacitinib		0	Pfizer	ChemSpider ChEMBL Guide to Pharmacology FDA SRS BindingDB			nan	0	337.2	1.5	91.0	5	2	5	nan	JAK1 JAK2 JAK3	Tyr	CNS(=O)(=O)C[C@H]1CC[C@@H](CC1)N(c2ncnc3c2cc[nH]3)C	HJWLJNBZVZDLAQ-HAQNSBGRSA-N	nan	None	Single Stereoisomer	JAK-I JAKI OCLACITINIB PF 03394197 PF-03394197
Emprumapimod		0	Pfizer	ChemSpider PubChem FDA SRS			NaN	0	473.2	3.3	102.5	6	2	10		nan	(*)	CC(C)CN1C2=CC(C(N[C@H](C(N)=O)CCN(C)C)=O)=C(OC3=C(C=C(C=C3)F)F)C=C2C=N1	JOOOJNJPZINWHM-IBGZPJMESA-N	NaN	None	Single Stereoisomer	PF-07265803 PF-06802861
Toceranib		0	Pfizer	ChemSpider ChEMBL PubChem RCSB PDBe ZINC FDA SRS BindingDB	'BWC'	6m13	nan	0	396.2	3.1	77.2	3	3	5	nan	KIT	KIT	Cc1c([nH]c(c1C(=O)NCCN2CCCC2)C)/C=C\3/c4cc(ccc4NC3=O)F	SRSGVKWWVXWSJT-ATVHPVEESA-N	nan	None	Achiral Molecule	PALLADIA PHA-291639 TOCERANIB
Ilunocitinib		0		ChemSpider ChEMBL PubChem FDA SRS			nan	0	383.1	1.2	120.6	7	1	5	nan	nan		N#CCC1(CN(C1)S(=O)(=O)C1CC1)N1C=C(C=N1)C1N=CN=C2NC=CC=12	RVOUEXFKIYNODQ-UHFFFAOYSA-N	nan	None	Achiral Molecule	ILUNOCITINIB LY-3411067 LY3411067
Vecabrutinib		1	Sunesis Pharmaceuticals	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology FDA SRS			nan	1	529.2	2.7	130.5	7	3	5	nan	nan		c1c(cc(cc1N[C@@H]2CCCN(C2=O)[C@H]3CN(CC[C@@H]3C(=O)N)c4c(c(ncn4)N)F)Cl)C(F)(F)F	QLRRJMOBVVGXEJ-XHSDSOJGSA-N	nan	None	Single Stereoisomer	BIIB-062 BSK-4841 FP-0182 FP0182 SNS-062 VECABRUTINIB
Tafetinib		1	Nanjing Yoko Biomedical	ChemSpider ChEMBL PubChem Guide to Pharmacology ZINC FDA SRS BindingDB			nan	0	424.2	3.7	77.2	3	3	6	nan	KDR FLT4 FLT1	Tyr	CCN(CC)CCNC(=O)c1c([nH]c\2c1CCC/C2=C/3\c4cc(ccc4NC3=O)F)C	KGSRYTUWXUESJK-FXBPSFAMSA-N	nan	None	Achiral Molecule	SIM 010603 SIM-010603 TAFETINIB
Lorpucitinib		1	Janssen	ChemSpider PubChem BindingDB			nan	0	408.2	2.9	119.6	6	3	6	nan	nan		CC(C)(O)CNC(=O)CC1=NC2=CNC3=NC=CC3=C2N1[C@@H]1CC[C@@H](CC#N)CC1	NJKMSBSVJSQUBU-UHFFFAOYSA-N	nan	NaN	NaN	LORPUCITINIB
Zeteletinib		1	Daiichi Sankyo	ChemSpider PubChem FDA SRS BindingDB			nan	2	500.2	5.3	99.4	7	1	7	nan	nan		CC(C)(C1C=C(NC(=O)CC2C=NC(=CC=2)C2C=C3C=C(OC)C(=CC3=NC=2)OC)ON=1)C(F)(F)F	KOLQINCWMXQEOF-UHFFFAOYSA-N	nan	None	Achiral Molecule	BOS-172738 DS-5010 BOS172738 BOS172738 HEMIADIPATE DS5010
Vebreltinib		1	Crown Bioscience	ChemSpider ChEMBL PubChem DrugBank FDA SRS BindingDB			nan	0	424.1	3.5	78.7	8	0	4	nan	nan		Cn1cc2cc(C(F)(F)c3nnc4ccc(-c5cnn(C6CC6)c5)nn34)c(F)cc2n1	QHXLXUIZUCJRKV-UHFFFAOYSA-N	nan	None	Achiral Molecule	APL-101 BOZITINIB CBI-3103 PLB-1001 VEBRELTINIB
Mubritinib		1	Takeda	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS			nan	1	468.2	6.1	66.0	6	0	10	nan	EGFR ERBB2	Tyr	c1cc(ccc1CCCCn2ccnn2)OCc3coc(n3)/C=C/c4ccc(cc4)C(F)(F)F	ZTFBIUXIQYRUNT-MDWZMJQESA-N	nan	None	Achiral Molecule	MUBRITINIB TAK-165
Empesertib		1	Bayer	ChemSpider ChEMBL PubChem RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'8QW'	5n9s 6tnb	nan	2	559.2	5.4	114.7	8	2	8	nan	nan		C[C@H](c1ccc(cc1)F)C(=O)Nc2ccc(cc2)c3ccc4nc(nn4c3)Nc5ccc(cc5OC)S(=O)(=O)C	NRJKIOCCERLIDG-GOSISDBHSA-N	nan	None	Single Stereoisomer	(-)-BAY-1161909 BAY 1161909 BAY-1161909 EMPESERTIB MPS1-IN-5
Olafertinib		1	Suzhou NeuPharma	ChemSpider ChEMBL PubChem Guide to Pharmacology ZINC FDA SRS BindingDB			nan	1	530.2	4.6	93.6	7	3	8	nan	nan		C=CC(=O)Nc1cccc(-c2cccc3cnc(Nc4ccc(N5CCN(CCO)CC5)c(F)c4F)nc23)c1	IDRGFNPZDVBSSE-UHFFFAOYSA-N	nan	None	Achiral Molecule	CK-101 OLAFERTINIB RX-518
Lifirafenib		1	BeiGene	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'3K3'	4r5y	nan	1	478.1	5.3	89.1	5	2	3	nan	nan		c1cc2c(cc1C(F)(F)F)[nH]c(n2)[C@H]3[C@H]4[C@@H]3Oc5c4cc(cc5)Oc6ccnc7c6CCC(=O)N7	NGFFVZQXSRKHBM-FKBYEOEOSA-N	nan	None	Single Stereoisomer	BEIGENE-283 BGB 283 BGB-283 LIFIRAFENIB
Vevorisertib		1	ArQule	ChemSpider ChEMBL PubChem FDA SRS			nan	2	586.3	5.5	119.2	8	2	6	nan	nan		CN(C1CCN(CC1)C1C=C(C=CC=1)C1=CC=C2N=C(C3C=CC=NC=3N)N(C2=N1)C1C=CC(=CC=1)C1(N)CCC1)C(C)=O	NZDSLYATTDIDPH-UHFFFAOYSA-N	nan	None	Achiral Molecule	VEVORISERTIB
Atuveciclib		1	Bayer	ChemSpider ChEMBL PubChem ZINC FDA SRS BindingDB			nan	0	387.1	3.6	100.9	7	2	6	nan	nan		COc1cc(F)ccc1-c1ncnc(Nc2cccc(C[S@](C)(=N)=O)c2)n1	ACWKGTGIJRCOOM-HHHXNRCGSA-N	nan	None	Single Stereoisomer	ATUVECICLIB
Avotaciclib		1	BeyondBio	ChemSpider ChEMBL PubChem DrugBank FDA SRS			nan	0	281.1	0.9	136.7	8	3	2	nan	nan		NC1N=C(C=CN=1)C1=CC=C(O)C(=N1)C1C=CN=C(N)N=1	VFVAQKKPFOPZEA-UHFFFAOYSA-N	nan	None	Achiral Molecule	AVOTACICLIB BEY-1107 BEY1107 CDK1 INHIBITOR BEY1107
Glumetinib		1	HaiHe Phaemaceutical	ChemSpider ChEMBL PubChem DrugBank FDA SRS			nan	1	459.1	2.1	117.8	11	0	4	nan	nan		Cn1cc(-c2cnc3cnn(S(=O)(=O)c4cnc5ccc(-c6cnn(C)c6)cn45)c3c2)cn1	RYBLECYFLJXEJX-UHFFFAOYSA-N	nan	None	Achiral Molecule	GLUMETINIB SC-C244 SCC244
Agerafenib		1	Ignyta	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	2	517.2	5.9	120.6	8	2	7	nan	nan		CC(C)(c1cc(no1)NC(=O)Nc2cccc(c2)Oc3c4cc(c(cc4ncn3)OC)OC)C(F)(F)F	DKNUPRMJNUQNHR-UHFFFAOYSA-N	nan	None	Achiral Molecule	AB-024 AC-013773 AGERAFENIB CEP-32496 RXDX 105 RXDX-105
Theliatinib		1	Hutchison MediPharma	ChemSpider PubChem ZINC FDA SRS			nan	0	442.2	3.5	82.6	6	2	4	nan	nan		CN1CC[C@H]2[C@@H]1CN(C2)C(=O)Nc3cc4c(cc3OC)ncnc4Nc5cccc(c5)C#C	FSXCKIBROURMFT-VGSWGCGISA-N	nan	NaN	NaN	XILIERTINIB
Selatinib		1	Qilu Pharmaceutical	ChemSpider ChEMBL PubChem Guide to Pharmacology FDA SRS BindingDB			nan	2	564.1	6.5	89.3	7	2	11	nan	EGFR ERBB2	Tyr	CS(=O)CCNCc1ccc(o1)c2ccc3c(c2)c(ncn3)Nc4ccc(c(c4)Cl)OCc5cccc(c5)F	OAMVGUFHZPRXOM-UHFFFAOYSA-N	nan	NaN	NaN
Henatinib		1	Jiangsu Hengrui Medicine	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	0	468.2	2.0	97.9	5	3	5	nan	KDR	Tyr	Cc1c([nH]c2c1C(=O)N(CCC2)C[C@@H](CN3CCOCC3)O)/C=C\4/c5cc(ccc5NC4=O)F	MCTXSDCWFQAGFS-UEXNTNOUSA-N	nan	None	Single Stereoisomer	HENATINIB
Pexmetinib		1	Array BioPharma	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS			nan	2	556.3	6.1	106.2	7	3	8	nan	MAPK14 TEK	Tyr CMGC	Cc1ccc(cc1)n2c(cc(n2)C(C)(C)C)NC(=O)NCc3cc(ccc3Oc4ccc5c(c4)cnn5CCO)F	LNMRSSIMGCDUTP-UHFFFAOYSA-N	nan	None	Achiral Molecule	ARRY-614 PEXMETINIB
Darovasertib		1	Novartis	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	0	472.2	3.1	135.9	8	3	4	nan	nan		CC1(N)CCN(c2cccnc2NC(=O)c2nc(-c3ncccc3C(F)(F)F)cnc2N)CC1	XXJXHXJWQSCNPX-UHFFFAOYSA-N	nan	None	Achiral Molecule	DAROVASERTIB IDE-196 IDE196 LXS-196 LXS196 NVP-LXS-196
Altiratinib		1	Deciphera Pharmaceuticals	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'A9I'	7q4a	nan	1	510.2	5.0	109.4	5	3	8	nan	MET TEK KDR NTRK1	Tyr	c1cc(ccc1NC(=O)C2(CC2)C(=O)Nc3cc(c(cc3F)Oc4ccnc(c4)NC(=O)C5CC5)F)F	GNNDEPIMDAZHRQ-UHFFFAOYSA-N	nan	None	Achiral Molecule	ALTIRATINIB DCC-2701 DP-5164
Recilisib	Ex-RAD;Ex-rad	1	Onconova Therapeutics	ChemSpider ChEMBL PubChem ZINC FDA SRS			nan	0	336.0	3.6	71.4	3	1	5	nan	nan		c1cc(ccc1CS(=O)(=O)/C=C/c2ccc(cc2)C(=O)O)Cl	KBEKQQJUNVQLDZ-MDZDMXLPSA-N	nan	None	Achiral Molecule	EX-RAD ON 01210 ON 01210.NA ON-01210 RECILISIB
Flonoltinib		1	Chengdu Zenitar Biomedical Technology	ChemSpider ChEMBL PubChem RCSB PDBe Guide to Pharmacology BindingDB	'36H'	7f7w	nan	0	467.3	4.0	82.3	8	2	8	nan	nan		CN(CCO)C1CCN(CC1)C1=CC=C(C=C1F)NC1N=C(C2C=NN(C=2)C(C)C)C(C)=CN=1	CVLXNRIQVFIVGY-UHFFFAOYSA-N	nan	NaN	NaN
Ravoxertinib		1	Genentech	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'6QB'	5k4i 5k4j 6oph	nan	0	440.1	3.2	97.9	8	2	6	nan	nan		Cn1c(ccn1)Nc2nccc(n2)c3ccn(c(=O)c3)[C@H](CO)c4ccc(c(c4)F)Cl	RZUOCXOYPYGSKL-GOSISDBHSA-N	nan	None	Single Stereoisomer	GDC-0994 GDC0994 RAVOXERTINIB RG-7842
Zotiraciclib		1	S*BIO	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	0	372.2	4.7	50.3	5	1	0	nan	nan		CN1C/C=C/CCOc2cccc(c2)-c3ccnc(n3)Nc4cccc(c4)C1	VXBAJLGYBMTJCY-NSCUHMNNSA-N	nan	None	Achiral Molecule	EX 45 EX45 SB-1317 SB-1317 FREE BASE SB1317 TG-02 TG02 ZOTIRACICLIB
Balamapimod		1	Wyeth	ChemSpider ChEMBL PubChem Guide to Pharmacology ZINC FDA SRS			nan	2	573.2	6.5	82.2	9	1	7	nan	RAF1 MAP2K1 MAP2K2	STE TKL	Cn1ccnc1Sc2ccc(cc2Cl)Nc3c4cc(c(cc4ncc3C#N)N5CCC(CC5)N6CCCC6)OC	CVAKNHIXTWLGJO-UHFFFAOYSA-N	nan	None	Achiral Molecule	BALAMAPIMOD MKI-833
Conteltinib		1	Centaurus Biopharma	ChemSpider ChEMBL PubChem Guide to Pharmacology FDA SRS BindingDB			nan	2	635.3	3.8	127.0	11	4	10	nan	nan		COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2	NPJCURIANJMFEO-UHFFFAOYSA-N	nan	None	Unknown	CONTELTINIB
Alofanib		1	Russian Pharmaceutical Technologies	ChemSpider ChEMBL PubChem ZINC FDA SRS			nan	0	413.1	3.5	139.5	6	2	6	nan	nan		Cc1cc([N+](=O)[O-])c(NS(=O)(=O)c2cccc(C(=O)O)c2)cc1-c1cccnc1	QUQGQIASFYWKAB-UHFFFAOYSA-N	nan	None	Achiral Molecule	ALOFANIB
Cenisertib		1	EMD Serono	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	0	451.2	2.5	99.4	7	3	6	nan	AURKA AURKB AURKC	Other	Cc1cc(ccc1N2CCN(CC2)C)Nc3ncc(c(n3)N[C@@H]4[C@@H]5C[C@H]([C@@H]4C(=O)N)C=C5)F	KSOVGRCOLZZTPF-QMKUDKLTSA-N	nan	None	Racemic Mixture	AS-703569 R-763
Fadraciclib		1	Cyclacel pharmaceuticals	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	0	397.3	3.6	100.8	8	3	8	nan	nan		CC[C@@H]([C@@H](C)O)Nc1nc(c2c(n1)n(cn2)C(C)C)NCc3cnc(cc3C)C	DLPIYBKBHMZCJI-WBVHZDCISA-N	nan	None	Unknown
Panulisib		1	Piramal Enterprises	ChemSpider PubChem Guide to Pharmacology ZINC			nan	1	527.2	4.8	134.5	9	1	3	nan	PIK3CA MTOR	Atypical	CC(C)(C#N)c1ccc(cn1)n2c3c4cc(ccc4ncc3n(c2=NC#N)C)c5cc(c(nc5)N)C(F)(F)F	VJLRLTSXTLICIR-UHFFFAOYSA-N	nan	None	Single Stereoisomer
Fisogatinib		1	Blueprint Medicines	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology FDA SRS			nan	1	502.1	4.5	94.6	7	2	7	nan	nan		C=CC(=O)N[C@H]1CCOC[C@H]1Nc1ncc2cc(-c3c(Cl)c(OC)cc(OC)c3Cl)ccc2n1	MGZKYOAQVGSSGC-DLBZAZTESA-N	nan	None	Single Stereoisomer	BLU-111362 BLU-554 BLU111362 FISOGATINIB X-439161 X439161
Gartisertib		1	Vertex Pharmaceuticals	ChemSpider ChEMBL PubChem FDA SRS BindingDB			nan	1	541.2	1.0	134.2	10	2	5	nan	nan		Nc1nn2cc(F)cnc2c1C(=O)Nc1cncc(F)c1N1CCC(C(=O)N2CCN(C3COC3)CC2)CC1	QAYHKBLKSXWOEO-UHFFFAOYSA-N	nan	None	Achiral Molecule	GARTISERTIB M 4344 M-4344 M4344 VX-803
Puquitinib		1	Zhejiang Medicine	ChemSpider ChEMBL PubChem Guide to Pharmacology FDA SRS			nan	0	317.1	3.2	91.4	6	3	4	nan	nan		c1cc2cc(ccc2nc1)Nc3nc4c(c(n3)NC5CC5)[nH]cn4	QUTFBURLXCODBH-UHFFFAOYSA-N	nan	None	Single Stereoisomer
Luxeptinib		1	CrystalGenomics	ChemSpider ChEMBL PubChem FDA SRS BindingDB			nan	1	495.1	5.5	98.9	3	4	4	nan	nan		Cc1c[nH]c(-c2ccc(-c3ccc(NC(=O)Nc4c(F)cc(F)cc4F)cc3F)c3c2C(=O)NC3)n1	MWHHJYUHCZWSLS-UHFFFAOYSA-N	nan	None	Achiral Molecule	CG'806 CG-026806 CG-806 CG026806 CG806 LUXEPTINIB
Omipalisib		1	GlaxosmithKline	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'ZIG'	3l08	1	1	505.1	4.8	107.0	7	1	6	nan	PIK3CA MTOR	Atypical	COc1c(cc(cn1)c2ccc3c(c2)c(ccn3)c4ccnnc4)NS(=O)(=O)c5ccc(cc5F)F	CGBJSGAELGCMKE-UHFFFAOYSA-N	nan	None	Achiral Molecule	GSK-2126458 GSK2126458 OMIPALISIB
Epitinib		1	Hutchison MediPharma	ChemSpider PubChem ZINC FDA SRS			nan	0	430.2	3.5	82.6	6	2	5	nan	nan		CCN1CCN(CC1)C(=O)NC2=C(C=C3C(=C2)C(=NC=N3)NC4=CC=CC(=C4)C#C)OC CCN1CCN(CC1)C(=O)NC1=CC2=C(NC3C=C(C=CC=3)C#C)N=CN=C2C=C1OC	DQAZPZIYEOGZAF-UHFFFAOYSA-N	nan	None	Single Stereoisomer	HMPL-813
Pamufetinib		1	Taiho Pharmaceutical	ChemSpider ChEMBL PubChem Guide to Pharmacology ZINC FDA SRS BindingDB			nan	1	518.1	4.6	101.6	6	3	7	nan	nan		CNC(=O)C1=CC2=C(C=CN=C2C=C1OC)OC3=C(C=C(C=C3)NC(=S)NC(=O)CC4=CC=CC=C4)F	ORRNXRYWGDUDOG-UHFFFAOYSA-N	nan	None	Single Stereoisomer
Lerociclib		1.5	G1 Therapeutics	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology FDA SRS BindingDB			nan	0	474.3	3.5	91.2	8	2	4	nan	nan		CC(C)N1CCN(CC1)c2ccc(nc2)Nc3ncc4cc5n(c4n3)C6(CCCCC6)CNC5=O	YPJRHEKCFKOVRT-UHFFFAOYSA-N	nan	None	Achiral Molecule	G1T38 G1T38 FREE BASE LEROCICLIB
Linperlisib		1.5	Shanghai Yingli Pharmaceutical	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology FDA SRS BindingDB			nan	1	588.3	3.0	130.0	10	2	8	nan	nan		CC(C)(C1CCN(CC1)Cc2cc(cc3c2nc(nc3c4cc(c(nc4)OC)NS(=O)(=O)C)N5CCOCC5)F)O	NVWKNQGHVMMAJW-UHFFFAOYSA-N	nan	NaN	NaN
Dubermatinib		1.5	Tolero Pharmaceuticals	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	1	515.2	3.6	93.7	8	2	8	nan	nan		CN1CCN(CC1)Cc2ccc(cc2)Nc3ncc(c(n3)Nc4ccccc4S(=O)(=O)N(C)C)Cl	YUAALFPUEOYPNX-UHFFFAOYSA-N	nan	None	Achiral Molecule	DUBERMATINIB HCL-2084 TP 0903 TP-0903 TP0903
Nedisertib		1.5	Merck	ChemSpider PubChem BindingDB			nan	0	481.1	3.8	93.5	8	1	5	nan	nan		COc1ccc(nn1)C(c2cc(c(cc2Cl)F)c3c4ccc(cc4ncn3)N5CCOCC5)O	MOWXJLUYGFNTAL-UHFFFAOYSA-N	nan	None	Single Stereoisomer	MSC-2490484A M-3814 MSC2490484A M3814 MSC 2490484A
Repotrectinib		1.5	TP Therapeutics	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology FDA SRS BindingDB	'7GI'	7vkn 7vko	nan	0	355.1	2.6	80.6	6	2	0	nan	nan		CC1CNC(=O)C2=C3N=C(C=CN3N=C2)NC(C4=C(O1)C=CC(=C4)F)C	FIKPXCOQUIZNHB-WDEREUQCSA-N	nan	None	Single Stereoisomer	REPOTRECTINIB TPX-0005 TRX-0005
Emavusertib		1.5	Aurigene Discovery Technologies	ChemSpider ChEMBL PubChem RCSB PDBe FDA SRS	'FJ0'	7c2v	nan	1	491.2	2.2	142.9	11	2	5	nan	nan		Cc1cc(-c2nc(C(=O)Nc3cc4oc(N5CCOCC5)nc4nc3N3CC[C@@H](O)C3)co2)ccn1	SJHNWSAWWOAWJH-MRXNPFEDSA-N	nan	NaN	NaN
Samuraciclib		1.5	Imperial College of Science, Technology and Medicine	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'I74'	5jq5 7b5o 7b5q	nan	0	394.2	2.8	86.5	7	4	7	nan	nan		CC(C)c1cnn2c(NCc3ccccc3)cc(NC[C@H]3CCNC[C@@H]3O)nc12	YCVGLKWJKIKVBI-MJGOQNOKSA-N	nan	None	Single Stereoisomer	CT-7001 CT7001 ICEC-0942 ICEC0942 SAMURACICLIB
Ningetinib		1.5	HEC Pharm	ChemSpider ChEMBL PubChem DrugBank ZINC FDA SRS BindingDB			nan	2	556.2	5.4	107.6	8	2	8	Ningetinib, also known as CT-053 or DE-120, is a VEGF and PDGF inhibitor potentially for the treatment of wet age-related macular degeneration.	nan		Cc1c(c(=O)n(n1C)c2ccccc2)C(=O)Nc3ccc(c(c3)F)Oc4ccnc5c4ccc(c5)OCC(C)(C)O	VQYYQSZNRVQLIS-UHFFFAOYSA-N	nan	None	Achiral Molecule	CT-053 FREE BASE CT-053-PTSA FREE BASE CT053PTSA FREE BASE NINGETINIB
Peposertib		1.5	Merck	ChemSpider ChEMBL PubChem DrugBank ZINC FDA SRS BindingDB			nan	0	334.2	1.3	114.7	8	2	8	nan	nan		COCCOc1c(cc(cc1OC)Cc2cnc(nc2N)N)OC	WSWJIZXMAUYHOE-UHFFFAOYSA-N	nan	NaN	NaN	TETROXOPRIM
Selitrectinib		1.5	Bayer	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology FDA SRS BindingDB			nan	0	380.2	2.7	75.4	6	1	0	nan	nan		C[C@@H]1CCc2c(cc(cn2)F)[C@H]3CCCN3c4ccn5c(n4)c(cn5)C(=O)N1	OEBIHOVSAMBXIB-SJKOYZFVSA-N	nan	None	Single Stereoisomer	LOXO-195 SELITRECTINIB
Elimusertib		1.5	Bayer	ChemSpider PubChem			nan	0	375.2	2.6	84.8	7	1	3	nan	nan		CC1COCCN1c2cc(c3ccnc(c3n2)c4ccn[nH]4)c5ccnn5C	YBXRSCXGRPSTMW-UHFFFAOYSA-N	nan	None	Single Stereoisomer	BAY 1895344 BAY-1895344 BAY1895344
Gandotinib		2	Eli Lilly	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS			nan	0	469.2	4.0	83.4	7	2	6	nan	JAK2	Tyr	Cc1cc(n[nH]1)Nc2cc(c3nc(c(n3n2)Cc4ccc(cc4F)Cl)C)CN5CCOCC5	SQSZANZGUXWJEA-UHFFFAOYSA-N	nan	None	Achiral Molecule	GANDOTINIB LY-2784544 LY2784544
Ebvaciclib		2	Pfizer	ChemSpider ChEMBL PubChem RCSB PDBe Guide to Pharmacology FDA SRS BindingDB	'WG1'	7kjs	nan	0	471.2	2.0	117.4	8	2	5	nan	nan		C[C@@]1(O)CCC[C@H]1n1c(=O)c(C(F)F)cc2cnc(NC3CCN(S(C)(=O)=O)CC3)nc21	QIEKHLDZKRQLLN-FOIQADDNSA-N	nan	None	Single Stereoisomer	EBVACICLIB PF-06873600
Tasurgratinib		2	Eisai	ChemSpider ChEMBL PubChem ZINC FDA SRS BindingDB			nan	1	587.3	4.5	127.2	9	3	11	nan	nan		CNC(=O)n1ccc2cc(Oc3ccnc(NC(=O)c4ccc(C5CCN(CCO)CC5)cc4)c3)c(OCCOC)cc21	IBHOLSBDZMIPPT-UHFFFAOYSA-N	nan	None	Achiral Molecule	E-7090 E7090 TASURGRATINIB
Miransertib		2	Merck	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS	'6S1'	5kcv	nan	1	432.2	5.1	95.6	6	2	4	nan	nan		c1ccc(cc1)c2ccc3c(n2)n(c(n3)c4cccnc4N)c5ccc(cc5)C6(CCC6)N	HNFMVVHMKGFCMB-UHFFFAOYSA-N	nan	None	Achiral Molecule	ARQ 092 ARQ 092 FREE BASE ARQ-092 MIRANSERTIB
Zimlovisertib		2	Pfizer	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'8CG'	5uiu	nan	0	361.1	1.6	103.5	5	2	6	nan	nan		CC[C@H]1[C@@H](COc2nccc3cc(C(N)=O)c(OC)cc23)NC(=O)[C@H]1F	JKDGKIBAOAFRPJ-ZBINZKHDSA-N	nan	None	Single Stereoisomer	PF 06650833 PF-06650833 ZIMLOVISERTIB
Sapitinib		2	Astrazeneca	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	0	473.2	3.8	88.6	7	2	7	nan	EGFR ERBB2 ERBB4 ERBB3	Tyr	CNC(=O)CN1CCC(CC1)Oc2cc3c(cc2OC)ncnc3Nc4cccc(c4F)Cl	DFJSJLGUIXFDJP-UHFFFAOYSA-N	nan	None	Achiral Molecule	AZD-8931 AZD8931 SAPITINIB
Milciclib		2	Nerviano Medical Sciences	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'P48'	2wih 5vc6 5vd1	1	0	460.3	2.6	91.2	8	2	4	nan	CDK1 NTRK1	Tyr CMGC	CC1(Cc2cnc(nc2-c3c1c(nn3C)C(=O)NC)Nc4ccc(cc4)N5CCN(CC5)C)C	RXZMYLDMFYNEIM-UHFFFAOYSA-N	nan	None	Achiral Molecule	MILCICLIB PHA 848125 PHA-848125
Paxalisib		2	Genentech	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	0	382.2	1.0	117.1	10	1	2	nan	nan		CC1(C)OCCn2c1nc1c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12	LGWACEZVCMBSKW-UHFFFAOYSA-N	nan	None	Achiral Molecule	G-02441729 G02441729 GDC-0084 GDC0084 PAXALISIB RG-7666
Seletalisib		2	UCB	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	1	482.1	5.2	90.5	6	1	4	nan	nan		c1cc2cc(c(nc2c(c1)Cl)c3ccc[n+](c3)[O-])[C@H](C(F)(F)F)Nc4c5c(cccn5)ncn4	LNLJHGXOFYUARS-OAQYLSRUSA-N	nan	None	Single Stereoisomer	SELETALISIB UCB-5857 UCB5857
Belvarafenib		2	Hanmi Pharmaceutical	ChemSpider ChEMBL PubChem RCSB PDBe FDA SRS BindingDB	'V1Y'	6xfp	nan	1	478.1	5.9	105.8	7	3	4	nan	nan		CC1=C(C2=C(C=C1)C(=NC=C2)NC3=C(C(=CC=C3)Cl)F)NC(=O)C4=CSC5=C4N=CN=C5N	KVCQTKNUUQOELD-UHFFFAOYSA-N	nan	None	Achiral Molecule	BELVARAFENIB
Sonolisib		2	Cascadian Therapeutics	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS			nan	1	525.2	3.1	119.4	9	1	8	nan	PIK3CA PIK3CB PIK3CG	Atypical	CC(=O)O[C@@H]1C[C@]2([C@@H](CCC2=O)C3=C1[C@]4([C@H](OC(=O)/C(=C/N(CC=C)CC=C)/C4=C(C3=O)O)COC)C)C	QIUASFSNWYMDFS-NILGECQDSA-N	nan	None	Single Stereoisomer	PX-866 SONOLISIB
Ifidancitinib		2	Rigel Pharmaceuticals	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology FDA SRS			nan	0	395.1	4.2	105.1	7	3	5	nan	nan		COc1cc(Nc2ncc(C)c(Nc3ccc4oc(=O)[nH]c4c3)n2)cc(C)c1F	OYFMQDVLFYKOPZ-UHFFFAOYSA-N	nan	None	Achiral Molecule	A-301 ATI-502 IFIDANCITINIB
Allitinib		2	Allist Pharmaceuticals	ChemSpider ChEMBL PubChem Guide to Pharmacology ZINC FDA SRS			nan	1	448.1	5.9	76.1	5	2	7	nan	ERBB2 EGFR	Tyr	C=CC(=O)Nc1ccc2c(c1)c(ncn2)Nc3ccc(c(c3)Cl)OCc4cccc(c4)F	MVZGYPSXNDCANY-UHFFFAOYSA-N	nan	None	Achiral Molecule	ALL-3 ALLITINIB ALS 1306 AST 1306 AST-1306 AST1306
Verosudil		2	Aerie Pharmaceutical	ChemSpider ChEMBL PubChem Guide to Pharmacology FDA SRS			nan	0	327.1	2.8	65.2	4	2	4	nan	nan		CN(C)C(c1ccsc1)C(=O)Nc2ccc3c(c2)cc[nH]c3=O	VDYRZXYYQMMFJW-UHFFFAOYSA-N	nan	None	Racemic Mixture	AR-12286 AR-12286 FREE BASE VEROSUDIL
Mirdametinib		2	Pfizer	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'4BM'	3eqg 3vvh 7juu 7jv0 7m0x	nan	0	482.0	2.5	90.8	5	4	7	nan	nan		O=C(NOC[C@H](O)CO)c1ccc(F)c(F)c1Nc1ccc(I)cc1F	SUDAHWBOROXANE-SECBINFHSA-N	nan	None	Single Stereoisomer	MIRDAMETINIB PD 0325901 PD 03525901 PD 901 PD-0325901
Riviciclib		2	Piramal Enterprises	ChemSpider ChEMBL PubChem Guide to Pharmacology ZINC FDA SRS BindingDB			nan	0	401.1	3.3	94.1	6	3	3	nan	CDK1 CDK4 CDK9	CMGC	CN1CC[C@H]([C@@H]1CO)c2c(cc(c3c2oc(cc3=O)c4ccccc4Cl)O)O	QLUYMIVVAYRECT-OCCSQVGLSA-N	nan	None	Racemic Mixture
Edicotinib		2	Janssen	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	1	461.3	6.0	103.7	5	2	4	nan	nan		CC1(CCC(=CC1)c2c(ccc(n2)C3CC(OC(C3)(C)C)(C)C)NC(=O)c4[nH]c(cn4)C#N)C	BNVPFDRNGHMRJS-UHFFFAOYSA-N	nan	None	Achiral Molecule	EDICOTINIB JNJ-40346527
Tozasertib		2	Merck	ChemSpider ChEMBL PubChem RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'VX6'	2f4j 2xyn 3amb 3e5a 4af3 4b8m 4jbq 4zog 5wnm 6brj 6gr9	1	0	464.2	3.5	102.1	8	3	7	nan	AURKA AURKB AURKC	Other	Cc1cc(n[nH]1)Nc2cc(nc(n2)Sc3ccc(cc3)NC(=O)C4CC4)N5CCN(CC5)C	GCIKSSRWRFVXBI-UHFFFAOYSA-N	nan	None	Achiral Molecule	MK-045 MK-0457 TOZASERTIB VX-68 VX-680
Golidocitinib		2	Astrazeneca	ChemSpider ChEMBL PubChem Guide to Pharmacology FDA SRS BindingDB			nan	0	489.3	2.7	116.2	9	3	7	nan	nan		COc1nn(C)cc1Nc1nccc(-c2c[nH]c3c(NC(=O)[C@@H](C)N4CCN(C)CC4)cccc23)n1	CVCVOSPZEVINRM-MRXNPFEDSA-N	nan	None	Single Stereoisomer	AZD-4205 AZD4205 GOLIDOCITINIB
Ropsacitinib		2	Pfizer	ChemSpider ChEMBL RCSB PDBe FDA SRS BindingDB	'UWM'	6x8g	nan	0	383.2	2.5	113.4	9	0	4	nan	nan		Cn1cc(-c2cn3nccc3c(-c3cnn([C@]4(CC#N)C[C@@H](C#N)C4)c3)n2)cn1	XPLZTJWZDBFWDE-OYOVHJISSA-N	nan	None	Achiral Molecule	PF-06826647 ROPSACITINIB
Doramapimod		2	Boehringer Ingelheim	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'B96'	1kv2 3fzs 3npc 4jvg 4twn 5n66 6gtt	2	2	527.3	6.0	80.7	6	2	7	nan	MAPK14	CMGC	Cc1ccc(cc1)n2c(cc(n2)C(C)(C)C)NC(=O)Nc3ccc(c4c3cccc4)OCCN5CCOCC5	MVCOAUNKQVWQHZ-UHFFFAOYSA-N	nan	None	Achiral Molecule	BIRB 796 BS BIRB-796 BIRB-796 BS DORAMAPIMOD
Pegcantratinib		2	Cephalon	ChemSpider ChEMBL PubChem			nan	1	536.2	4.1	104.0	8	1	3	nan	nan		COCCN1C(=O)O[C@@]2(C[C@H]3O[C@]2(C)n2c4ccccc4c4c5c(c6c7ccccc7n3c6c42)C(=O)NC5)C1=O	SHWPFRVVBIKGAT-LYWBODIJSA-N	nan	None	Single Stereoisomer	CT-327 CT327 PEGCANTRATINIB SNA-120
Nezulcitinib		2	Theravance Biopharma	ChemSpider ChEMBL PubChem Guide to Pharmacology FDA SRS			nan	1	527.3	3.8	104.4	6	3	6	nan	nan		CN(C)C1CN(C1)C(=O)[C@@H]1CC2NC(=NC=2CN1C(C)C)C1=NNC2=CC(=CC=C21)C1C=CC(O)=CC=1CC	VQIIUJSNIKEMCK-MHZLTWQESA-N	nan	None	Single Stereoisomer	NEZULCITINIB TD-0903 THRX-136377
Silmitasertib		2	Senhwa Biosciences	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'3NG'	3nga 3pe1 5o11 6fyl 6fyp 6fyv 6hmb 6isj 6k3l 6khd 6khe 6khf 6p5s	1	0	349.1	4.9	75.1	4	2	3	nan	CSNK2A1 CSNK2A2	Other	c1cc(cc(c1)Cl)Nc2c3ccncc3c4ccc(cc4n2)C(=O)O	MUOKSQABCJCOPU-UHFFFAOYSA-N	nan	None	Achiral Molecule	CX 4945 CX-4945 CX-4945 FREE ACID CX4945 SILMITASERTIB
Nemiralisib		2	GlaxosmithKline	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'VVX'	5ae8	nan	0	440.2	4.9	77.0	5	2	5	nan	nan		CC(C)N1CCN(CC1)Cc2cnc(o2)c3cc(cc4c3cn[nH]4)c5cccc6c5cc[nH]6	MCIDWGZGWVSZMK-UHFFFAOYSA-N	nan	None	Achiral Molecule	GSK-2269557 GSK-2269557 FREE BASE GSK-2269557A GSK2269557A NEMIRALISIB
Apitolisib		2	Hoffmann-La Roche	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'980'	3tl5	nan	1	498.2	0.9	133.8	11	2	5	nan	PIK3CA MTOR	Atypical	Cc1c(sc2c1nc(nc2N3CCOCC3)c4cnc(nc4)N)CN5CCN(CC5)C(=O)[C@H](C)O	YOVVNQKCSKSHKT-HNNXBMFYSA-N	nan	None	Single Stereoisomer	APITOLISIB G-038390 G-038390.1 GDC-0980 GDC-0980.1 GNE-390 RG-7422 RG7422
Neflamapimod		2	EIP Pharma	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'52P'	3fc1 3hp5 3zsi	nan	1	435.0	5.5	47.3	5	0	3	nan	MAPK14	CMGC	c1cc(c(c(c1)Cl)c2c3ccc(nn3cnc2=O)Sc4ccc(cc4F)F)Cl	VEPKQEUBKLEPRA-UHFFFAOYSA-N	nan	None	Achiral Molecule	745 NEFLAMAPIMOD VD-31 VD-31,745 VD-31745 VRT-031745 VX-745
Onvansertib		2	Cardiff Oncology	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'937'	2yac	nan	1	532.2	1.9	134.7	10	3	7	nan	nan		CN1CCN(CC1)c2ccc(c(c2)Nc3ncc4c(n3)-c5c(c(nn5CCO)C(=O)N)CC4)OC(F)(F)F	QHLVBNKYJGBCQJ-UHFFFAOYSA-N	nan	None	Achiral Molecule	NMS-1286937 NMS-P937 ONVANSERTIB PCM-075
Lucitanib		2	Clovis Oncology	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'3ZC'	4rwl	1	0	443.2	4.4	95.7	6	2	7	nan	FLT1 KDR FLT4 FGFR1 FGFR2	Tyr	CNC(=O)c1cccc2c1ccc(c2)Oc3ccnc4c3cc(c(c4)OCC5(CC5)N)OC	CUDVHEFYRIWYQD-UHFFFAOYSA-N	nan	None	Achiral Molecule	AL-3810 CO-3810 E-3810 LUCITANIB S 80881 S-80881
Foslinanib		2	TaiRx	ChemSpider ChEMBL PubChem DrugBank ZINC FDA SRS			nan	0	365.0	2.8	108.8	4	3	4	nan	nan		COc1ccc2c(c1OP(=O)(O)O)c(=O)cc([nH]2)c3cccc(c3)F	ZDWFMAHQGDEALT-UHFFFAOYSA-N	nan	None	Achiral Molecule	CVM-1118 CVM-1118 FREE ACID FOSLINANIB TRX 818 TRX-818 TRX-818 FREE ACID
Adavosertib		2	Astrazeneca	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'8X7'	5v5y 5vd0 5vdk	1	1	500.3	2.9	104.3	10	2	7	nan	WEE1	Other	CC(C)(c1cccc(n1)n2c3c(cnc(n3)Nc4ccc(cc4)N5CCN(CC5)C)c(=O)n2CC=C)O	BKWJAKQVGHWELA-UHFFFAOYSA-N	nan	None	Achiral Molecule	ADAVOSERTIB AZD 1775 AZD-1775 AZD1775 MK-1775 MK1775
Acumapimod		2	Mereo BioPharma	ChemSpider PubChem DrugBank Guide to Pharmacology ZINC FDA SRS			nan	0	385.2	2.8	113.8	6	2	5	nan	MAPK14 MAPK11 MAPK13 MAPK12	CMGC	Cc1ccc(cc1n2c(c(cn2)C(=O)c3cccc(c3)C#N)N)C(=O)NC4CC4	VGUSQKZDZHAAEE-UHFFFAOYSA-N	nan	None	Single Stereoisomer	ACUMAPIMOD
Olmutinib		2	Hanmi Pharmaceutical	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	1	486.2	5.1	82.6	8	2	7	For use in treatment of metastatic T790M mutation positive non-small cell lung cancer	EGFR	Tyr	CN1CCN(CC1)c2ccc(cc2)Nc3nc4ccsc4c(n3)Oc5cccc(c5)NC(=O)C=C	FDMQDKQUTRLUBU-UHFFFAOYSA-N	nan	None	Achiral Molecule	BI 1482694 BI-1482694 HM-61713 HM61713 OLMUTINIB
Afuresertib		2	GlaxoSmithKline	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	0	426.0	3.9	72.9	5	2	6	nan	AKT1 AKT2 AKT3	AGC	Cn1c(c(cn1)Cl)c2cc(sc2Cl)C(=O)N[C@@H](Cc3cccc(c3)F)CN	AFJRDFWMXUECEW-LBPRGKRZSA-N	nan	None	Single Stereoisomer	AFURESERTIB ASB-183 ASB183 GSK-2110183 GSK-2110183C GSK2110183 GSK2110183C
Dalpiciclib		2	Jiangsu Hengrui Medicine	ChemSpider ChEMBL PubChem Guide to Pharmacology FDA SRS			nan	0	446.2	4.0	101.8	8	2	5	nan	nan		CC(=O)c1c(C)c2cnc(Nc3ccc(C4CCNCC4)cn3)nc2n(C2CCCC2)c1=O	SGJLSPUSUBJWHO-UHFFFAOYSA-N	nan	None	Achiral Molecule	DALPICICLIB SHR-6390
Amcasertib		2	Boston Biomedical	ChemSpider ChEMBL PubChem DrugBank ZINC FDA SRS			nan	2	539.2	6.0	90.1	5	3	9	nan	PDGFRA	Tyr	CCN(CC)CCNC(=O)c1c(c([nH]c1C)/C=C\2/c3cc(ccc3NC2=O)c4csc(n4)c5ccccc5)C	QDWKGEFGLQMDAM-ULJHMMPZSA-N	nan	None	Achiral Molecule	AMCASERTIB BBI-503 BBI503
Derazantinib		2	ArQule	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology FDA SRS			nan	1	468.2	5.5	59.1	5	2	9	Derazantinib (ARQ087) is an orally bioavailable, non-selective FGFR inhibitor being investigated for antineoplastic activity.	nan		COCCNCCc1cccc(c1)Nc2ncc3c(n2)-c4ccccc4[C@@H](C3)c5ccccc5F	KPJDVVCDVBFRMU-AREMUKBSSA-N	nan	None	Single Stereoisomer	ARQ 087 ARQ-087 ARQ087 DERAZANTINIB
Eganelisib		2	Intellikine	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'V7Y'	6xrl 7jwz	nan	1	528.2	3.2	125.1	9	2	4	nan	nan		C[C@@H](c1cc2cccc(c2c(=O)n1c3ccccc3)C#Cc4cnn(c4)C)NC(=O)c5c(nn6c5nccc6)N	XUMALORDVCFWKV-IBGZPJMESA-N	nan	None	Single Stereoisomer	EGANELISIB IPI-549 PI3K-GAMMA INHIBITOR IPI-549
Elsubrutinib		2	Abbvie	ChemSpider ChEMBL PubChem Guide to Pharmacology ZINC FDA SRS			nan	0	297.1	2.2	79.2	2	2	3	nan	nan		C=CC(=O)N1CCC[C@@H](c2ccc(C(N)=O)c3[nH]ccc23)C1	UNHZLHSLZZWMNP-LLVKDONJSA-N	nan	None	Single Stereoisomer	ABBV-105 ABBV105 ELSUBRUTINIB
Entospletinib		2	Gilead Sciences	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'CG9'	4puz	1	0	411.2	3.9	83.4	7	2	4	nan	SYK	Tyr	c1cc(ccc1Nc2c3nccn3cc(n2)c4ccc5cn[nH]c5c4)N6CCOCC6	XSMSNFMDVXXHGJ-UHFFFAOYSA-N	nan	None	Achiral Molecule	ENTOSPLETINIB GS-9973 SYK INHIBITOR GS-9973
Ceralasertib		2	Astrazeneca	ChemSpider PubChem			nan	0	412.2	2.9	107.8	7	2	4	Ceralasertib, also known as AZD6738, is an orally available morpholino-pyrimidine-based inhibitor of ataxia telangiectasia and rad3 related (ATR) kinase, with potential antineoplastic activity. Upon oral administration, ATR kinase inhibitor Ceralasertib selectively inhibits ATR activity by blocking the downstream phosphorylation of the serine/threonine protein kinase CHK1. This prevents ATR-mediated signaling, and results in the inhibition of DNA damage checkpoint activation, disruption of DNA damage repair, and the induction of tumor cell apoptosis.	nan		CC1COCCN1c2cc(nc(n2)c3cncc4c3cc[nH]4)C5(CC5)S(=N)(=O)C	DTTJKLNXNZAVSM-UHFFFAOYSA-N	nan	None	Single Stereoisomer	AZD-6738 AZD6738
Foretinib		2	GlaxoSmithKline	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'88Z'	3lq8 5ia4 6i2y 6sd9 6sdc	2	2	632.2	5.8	111.2	8	2	12	nan	MET KDR	Tyr	COc1cc2c(ccnc2cc1OCCCN3CCOCC3)Oc4ccc(cc4F)NC(=O)C5(CC5)C(=O)Nc6ccc(cc6)F	CXQHYVUVSFXTMY-UHFFFAOYSA-N	nan	None	Achiral Molecule	EXEL-2880 FORETINIB GSK-089 GSK-1363089 GSK-1363089G GSK089 GSK1363089 GSK1363089G XL-880 XL880
Galunisertib		2	Eli Lilly	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	0	369.2	3.5	86.7	5	1	3	nan	TGFBR1	TKL	Cc1cccc(n1)c2c(c3n(n2)CCC3)c4ccnc5c4cc(cc5)C(=O)N	IVRXNBXKWIJUQB-UHFFFAOYSA-N	nan	None	Achiral Molecule	GALUNISERTIB LY-2157299 LY2157299
Glesatinib		2	Mirati Therapeutics	ChemSpider ChEMBL PubChem DrugBank ZINC FDA SRS			nan	2	619.2	6.2	97.4	8	3	11	nan	MET TEK FLT1 KDR FLT4 MST1R	Tyr	COCCNCc1ccc(nc1)c2cc3c(s2)c(ccn3)Oc4ccc(cc4F)NC(=S)NC(=O)Cc5ccc(cc5)F	YRCHYHRCBXNYNU-UHFFFAOYSA-N	nan	None	Achiral Molecule	GLESATINIB MG-90265 MG-90265X MG90265 MG90265GLY MG90265H9 MG90265X MGCD-265 MGCD265
Golvatinib		2	Eisai	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'GV0'	5ia5	2	1	633.3	4.8	119.1	7	3	8	nan	MET KDR	Tyr	CN1CCN(CC1)C2CCN(CC2)C(=O)Nc3cc(ccn3)Oc4ccc(c(c4)F)NC(=O)C5(CC5)C(=O)Nc6ccc(cc6)F	UQRCJCNVNUFYDX-UHFFFAOYSA-N	nan	None	Achiral Molecule	E-7050 E7050 GOLVATINIB
Ilorasertib	ABT-348, A-968660;Abt-348, a-968660	2	Abbott Laboratories	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	1	488.1	5.2	118.1	7	4	6	nan	AURKA AURKB AURKC FLT1 PDGFRA PDGFRB	Tyr Other	c1cc(cc(c1)F)NC(=O)Nc2ccc(cc2)c3csc4c3c(ncc4c5cnn(c5)CCO)N	WPHKIQPVPYJNAX-UHFFFAOYSA-N	nan	None	Achiral Molecule	A-968660 A-968660.0 ABBOTT-968660 ABT-348 ABT-348, A-968660 ILORASERTIB
Brepocitinib		2	Pfizer	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'G4J'	6dbm 6dbn	nan	0	389.2	1.8	79.2	7	1	4	nan	nan		Cn1cc(cn1)Nc2nccc(n2)N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]5CC5(F)F	BUWBRTXGQRBBHG-MJBXVCDLSA-N	nan	None	Single Stereoisomer	BREPOCITINIB PF-06700841
Nemtabrutinib		2	Merck	ChemSpider ChEMBL PubChem RCSB PDBe FDA SRS	'HRA'	6e4f	nan	0	478.1	4.6	109.4	7	3	7	nan	nan		c1ccc(cc1)Oc2ccc(c(c2)Cl)C(=O)c3c[nH]c4c3c(ncn4)N[C@@H]5CC[C@H](OC5)CO	JSFCZQSJQXFJDS-QAPCUYQASA-N	nan	NaN	NaN
Branebrutinib		2	Bristol Myers Squibb	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology FDA SRS BindingDB			nan	0	370.2	2.1	91.2	3	3	3	nan	nan		CC#CC(=O)N[C@H]1CCCN(C1)c2c(cc(c3c2c(c([nH]3)C)C)C(=O)N)F	VJPPLCNBDLZIFG-ZDUSSCGKSA-N	nan	None	Single Stereoisomer	BMS-986195 BRANEBRUTINIB
Bimiralisib		2	Piqur Therapeutics	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'A3W'	5oq4	nan	0	411.2	1.0	103.2	8	2	3	Bimiralisib (PQR309) is a novel dual inhibitor of phosphoinositol 3-kinase (PI3K) and mechanistic target of rapamycin (mTOR) kinases, with expected utility as an anti-cancer agent.	nan		c1c(c(c[nH]c1=N)c2nc(nc(n2)N3CCOCC3)N4CCOCC4)C(F)(F)F	ADGGYDAFIHSYFI-UHFFFAOYSA-N	nan	None	Achiral Molecule	BIMIRALISIB NC-B5 NCB5 PI3K-IN-2 PQR-309 PQR309
Berzosertib		2	Vertex Pharmaceuticals	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	0	463.2	3.9	124.0	8	2	7	nan	nan		CC(C)S(=O)(=O)c1ccc(cc1)c2cnc(c(n2)c3cc(no3)c4ccc(cc4)CNC)N	JZCWLJDSIRUGIN-UHFFFAOYSA-N	nan	None	Achiral Molecule	BERZOSERTIB M-6620 M6620 VE-822 VX-970 VX970
Bemcentinib		2	BerGenBio	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	1	506.3	4.9	97.8	8	2	4	nan	AXL	Tyr	c1ccc-2c(c1)CCCc3c2nnc(c3)n4c(nc(n4)Nc5ccc6c(c5)CC[C@H](CC6)N7CCCC7)N	KXMZDGSRSGHMMK-VWLOTQADSA-N	nan	None	Single Stereoisomer	BEMCENTINIB BGB 324 BGB-324 BGB324 CS-1046 HY-15150 KB-80319 QC-11751 R 428 R-428 R428 SYN-1131 SYN1131 W-5845
Defactinib		2	Verastem	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'7KD'	5mah	1	1	510.1	2.4	142.1	9	3	8	nan	PTK2 PTK2B	Tyr	CNC(=O)c1ccc(cc1)Nc2ncc(c(n2)NCc3c(nccn3)N(C)S(=O)(=O)C)C(F)(F)F	FWLMVFUGMHIOAA-UHFFFAOYSA-N	nan	None	Achiral Molecule	DEFACTINIB PF-04554878 VS-6063
Bafetinib		2	Innovive Pharmaceuticals	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'406'	2e2b	2	2	576.3	5.4	99.2	8	2	8	nan	LYN ABL1	Tyr	Cc1ccc(cc1Nc2nccc(n2)c3cncnc3)NC(=O)c4ccc(c(c4)C(F)(F)F)CN5CC[C@@H](C5)N(C)C	ZGBAJMQHJDFTQJ-DEOSSOPVSA-N	nan	None	Single Stereoisomer	BAFETINIB CNS-9 INNO-406 NS-187
Amuvatinib		2	Supergen	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	0	447.1	3.3	75.9	7	1	3	Amuvatinib is a selective multi-targeted tyrosine kinase inhibitor that suppresses c-MET, c-RET and the mutant forms of c-KIT, PDGFR and FLT3. Amuvatinib also suppresses Rad51 protein, a critical comp\nonent of double-stranded DNA repair in cancer cells.	KIT MET RET FLT3 PDGFRB	Tyr	c1ccc2c(c1)c3c(o2)c(ncn3)N4CCN(CC4)C(=S)NCc5ccc6c(c5)OCO6	FOFDIMHVKGYHRU-UHFFFAOYSA-N	nan	None	Achiral Molecule	AMUVATINIB HPK 56 HPK-56 HPK56 MP 470 MP-470 MP470
Pilaralisib		2	Sanofi	ChemSpider ChEMBL PubChem DrugBank ZINC FDA SRS BindingDB			nan	1	540.1	4.5	148.3	8	4	8	nan	PIK3CA PIK3CB PIK3CD PIK3CG	Atypical	CC(C)(C(=O)Nc1cccc(c1)S(=O)(=O)Nc2c(nc3ccccc3n2)Nc4cc(ccc4Cl)OC)N	QINPEPAQOBZPOF-UHFFFAOYSA-N	nan	None	Achiral Molecule	PILARALISIB SAR-245408 SAR245408 XL-147 XL147
Ivarmacitinib		2	Jiangsu Hengrui Medicine	ChemSpider PubChem			NaN	0	414.2	2.2	112.2	8	2	4		nan	(*)	CN(C1C[C@@H]2CN(C[C@@H]2C1)C(=O)NC1=NC(=NS1)OC)C1=NC=NC2NC=CC=21	DNBCBAXDWNDRNO-FOSCPWQOSA-N	NaN	NaN	NaN	IVARMACITINIB
Pamapimod		2	Hoffmann-La Roche	ChemSpider ChEMBL PubChem RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'FLW'	3flw	1	0	406.1	1.9	109.5	8	3	8	nan	MAPK14 MAPK11	CMGC	Cn1c2c(cc(c1=O)Oc3ccc(cc3F)F)cnc(n2)NC(CCO)CCO	JYYLVUFNAHSSFE-UHFFFAOYSA-N	nan	None	Achiral Molecule	PAMAPIMOD R-1503 R1503 RO 4402257 RO-4402257
Pirotinib		2	XuanZhu Pharma	ChemSpider PubChem FDA SRS BindingDB			NaN	2	509.2	5.8	79.4	6	2	7		nan	(*)	CN1CCC2(CC1)CC(C2)COc3cc4c(cc3NC(=O)C=C)c(ncn4)Nc5ccc(c(c5)Cl)F	KJBZQIKLKWQVLL-UHFFFAOYSA-N	NaN	NaN	NaN	KBP-5209
Pimasertib	as703026; emd 1036239;AS703026;EMD 1036239;MSC1936369A;Msc1936369a;Msc1936369a; as703026; emd 1036239;as703026	2	Merck	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'QOA'	7m0w	nan	0	431.0	1.7	94.5	5	4	6	nan	MAP2K1 MAP2K2	STE	c1cc(c(cc1I)F)Nc2cnccc2C(=O)NC[C@@H](CO)O	VIUAUNHCRHHYNE-JTQLQIEISA-N	nan	None	Single Stereoisomer	AS 703026 AS-703026 AS703026 EMD 1036239 EMD-1036239 G-02443714 MSC-1936369 MSC-1936369A MSC-1936369B MSC1936369A MSC1936369A; AS703026; EMD 1036239 PIMASERTIB
Pictilisib		2	Hoffmann-La Roche	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'GD9'	2wxp 2y3a 3dbs	1	1	513.2	2.1	107.6	9	1	5	nan	PIK3CA PIK3CB PIK3CD PIK3CG	Atypical	CS(=O)(=O)N1CCN(CC1)Cc2cc3c(s2)c(nc(n3)c4cccc5c4cn[nH]5)N6CCOCC6	LHNIIDJUOCFXAP-UHFFFAOYSA-N	nan	None	Achiral Molecule	CDC-0941 GDC 0941 GDC-0941 PICTILISIB PICTRELISIB RG-7321
Gusacitinib		2	Asana BioSciences	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology FDA SRS			nan	0	460.2	2.5	134.1	9	3	5	nan	nan		N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1	NLFLXLJXEIUQDL-UHFFFAOYSA-N	nan	None	Achiral Molecule	ASN-002 ASN002 EN-3351 EN3351 GUSACITINIB
Sapanisertib		2	Takeda	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'FE5'	6gvf	nan	0	309.1	2.4	121.7	8	2	2	nan	MTOR	Atypical	CC(C)n1c2c(c(n1)c3ccc4c(c3)nc(o4)N)c(ncn2)N	GYLDXIAOMVERTK-UHFFFAOYSA-N	nan	None	Achiral Molecule	INK-128 INK128 MLN-0128 MLN0128 SAPANISERTIB TAK-228
Serabelisib		2	Takeda	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	0	363.1	2.2	98.9	7	1	2	nan	nan		c1cc2c(cc1c3ccc4ncc(n4c3)C(=O)N5CCOCC5)nc(o2)N	BLGWHBSBBJNKJO-UHFFFAOYSA-N	nan	None	Achiral Molecule	AGN-PC-0DB6FL INK1117 MLN-1117 MLN1117 SERABELISIB TAK-117
Vorolanib		2	Tyrogenex	ChemSpider ChEMBL PubChem DrugBank FDA SRS			nan	0	439.2	2.7	97.5	3	3	3	nan	nan		Cc1c([nH]c(c1C(=O)N[C@H]2CCN(C2)C(=O)N(C)C)C)/C=C\3/c4cc(ccc4NC3=O)F	KMIOJWCYOHBUJS-HAKPAVFJSA-N	nan	None	Single Stereoisomer	VOROLANIB
Sotrastaurin		2	Novartis	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'LW4'	3iw4	nan	0	438.2	2.4	94.2	6	2	3	nan	nan		CN1CCN(CC1)c2nc3ccccc3c(n2)C4=C(C(=O)NC4=O)c5c[nH]c6c5cccc6	OAVGBZOFDPFGPJ-UHFFFAOYSA-N	nan	None	Achiral Molecule	AEB-071 AEB071 NVP-AEB071 SOTRASTAURIN
Poseltinib		2	Hanmi Pharmaceutical	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology FDA SRS BindingDB			nan	0	470.2	4.6	95.8	8	2	7	nan	nan		CN1CCN(CC1)c2ccc(cc2)Nc3nc4ccoc4c(n3)Oc5cccc(c5)NC(=O)C=C	LZMJNVRJMFMYQS-UHFFFAOYSA-N	nan	None	Achiral Molecule	HM71224 LY3337641 POSELTINIB
Vodobatinib		2	Sun Pharma Advanced Research Company	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology FDA SRS			nan	0	453.1	5.0	71.1	3	2	2	nan	nan		Cc1ccc(C(=O)NNC(=O)c2c(C)cccc2Cl)cc1C#Cc1cnc2ccccc2c1	ZQOBVMHBVWNVBG-UHFFFAOYSA-N	nan	None	Achiral Molecule	K-0706 K0706 SCO-088 VODOBATINIB
Vistusertib		2	Astrazeneca	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	0	462.2	2.5	92.7	8	1	4	nan	MTOR	Atypical	C[C@H]1COCCN1c2c3ccc(nc3nc(n2)N4CCOC[C@@H]4C)c5cccc(c5)C(=O)NC	JUSFANSTBFGBAF-IRXDYDNUSA-N	nan	None	Single Stereoisomer	AZD-2014 AZD2014 VISTUSERTIB
Solcitinib		2	GlaxoSmithKline	ChemSpider ChEMBL PubChem Guide to Pharmacology ZINC FDA SRS BindingDB			nan	0	389.2	3.2	79.6	5	1	4	nan	JAK1	Tyr	CC1(CN(C1)C(=O)c2ccc(cc2)c3cccc4n3nc(n4)NC(=O)C5CC5)C	MPYACSQFXVMWNO-UHFFFAOYSA-N	nan	None	Achiral Molecule	G-154578 G154578 GLPG-0778 GLPG-0788 GLPG0778 GSK-2586184 GSK-2586184A GSK2586184A SOLCITINIB
Vactosertib		2	MedPacto	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	0	399.2	4.2	83.8	6	2	5	Vactosertib (EW-7197) acts as in inhibitor of transforming growth factor beta receptor 1B (ALK5) and activin A receptor type IB (ALK4). The compound is potent, selective, and orally bioavailable, and exhibits experimental anti-tumour activity.	nan		Cc1cccc(n1)c2c(nc([nH]2)CNc3ccccc3F)c4ccc5ncnn5c4	FJCDSQATIJKQKA-UHFFFAOYSA-N	nan	None	Achiral Molecule	EW-7197 TEW 7197 TEW-7197 VACTOSERTIB
Uprosertib		2	GlaxoSmithKline	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	0	428.1	3.6	86.1	5	2	6	nan	AKT1 AKT2 AKT3	AGC	Cn1c(c(cn1)Cl)c2cc(oc2Cl)C(=O)N[C@@H](Cc3ccc(c(c3)F)F)CN	AXTAPYRUEKNRBA-JTQLQIEISA-N	nan	None	Single Stereoisomer	AKT INHIBITOR GSK-2141795 AKT INHIBITOR GSK2141795 GSK-2141795 GSK-2141795C GSK2141795 GSK2141795C UPROSERTIB
Dilmapimod		2	GlaxoSmithKline	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS			nan	0	456.1	2.9	100.3	7	3	6	Dilmapimod has been used in trials studying the treatment and diagnostic of Nerve Trauma, Inflammation, Pain, Neuropathic, Arthritis, Rheumatoid, and Coronary Heart Disease, among others.	MAPK14 MAPK11 MAPK13 MAPK12	CMGC	Cc1cc(ccc1c2c3ccc(=O)n(c3nc(n2)NC(CO)CO)c4c(cccc4F)F)F	ORVNHOYNEHYKJG-UHFFFAOYSA-N	nan	None	Achiral Molecule	DILMAPIMOD GW-681323 SB-681323 SB681323
Ulixertinib		2	BioMed Valley Discoveries	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS	'EVK'	6gdq	nan	0	432.1	4.7	90.0	4	4	7	nan	MAPK1 MAPK3	CMGC	CC(C)Nc1cc(c(cn1)Cl)c2cc([nH]c2)C(=O)N[C@H](CO)c3cccc(c3)Cl	KSERXGMCDHOLSS-LJQANCHMSA-N	nan	None	Single Stereoisomer	BVD-523 BVD-ERK ULIXERTINIB VRT-752271
Tovorafenib		2	Sunesis Pharmaceuticals	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'QOP'	6v34	nan	1	505.0	4.0	135.8	8	3	5	nan	nan		CC(C1=NC=C(S1)C(=O)NC2=NC=C(C(=C2)C(F)(F)F)Cl)NC(=O)C3=C(C(=NC=N3)N)Cl	VWMJHAFYPMOMGF-ZCFIWIBFSA-N	nan	NaN	NaN	BIIB-024 BIIB024 MLN-2480 TAK 580 TAK-580
Naporafenib		2	Novartis	ChemSpider ChEMBL PubChem RCSB PDBe Guide to Pharmacology FDA SRS BindingDB	'K81'	6n0p	nan	1	502.2	3.9	96.8	7	2	7	nan	nan		Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1	UEPXBTCUIIGYCY-UHFFFAOYSA-N	nan	None	Achiral Molecule	LXH 254 LXH-254 LXH254 NAPORAFENIB PAN-RAF INHIBITOR LXH254
Tomivosertib		2	Effector Therapeutics	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'N45'	6ck6	nan	0	340.2	1.6	114.9	7	3	2	Tomivosertib, also known as eFT508 is a MNK1/2 inhibitor. Tomivosertib binds to and inhibits the activity of MNK1 and 2. This prevents MNK1/2-mediated signaling, and inhibits the phosphorylation of certain regulatory proteins, including eukaryotic translation initiation factor 4E (eIF4E), that regulate the translation of messenger RNAs (mRNAs) involved in tumor cell proliferation, angiogenesis, survival and immune signaling	nan		Cc1cc(c(=O)n2c1C(=O)NC23CCCCC3)Nc4cc(ncn4)N	HKTBYUWLRDZAJK-UHFFFAOYSA-N	nan	None	Achiral Molecule	EFT 508 EFT-508 EFT508 TOMIVOSERTIB
Tirabrutinib		2	Ono Pharmaceutical	ChemSpider PubChem			nan	0	454.2	2.8	108.3	8	1	4	nan	nan		CC#CC(=O)N1CCC(C1)n2c3c(c(ncn3)N)n(c2=O)c4ccc(cc4)Oc5ccccc5	SEJLPXCPMNSRAM-UHFFFAOYSA-N	nan	None	Single Stereoisomer	ONO-4059(FREE BASE) GS-4059 ONO-4059
Merestinib		2	Eli Lilly	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'L1X'	4eev 7aay	2	2	552.2	5.7	106.8	7	2	6	nan	MET	Tyr	Cc1ccc(c(=O)n1c2ccc(cc2)F)C(=O)Nc3ccc(c(c3)F)Oc4cc5cnn(c5cc4c6c[nH]nc6)C	QHADVLVFMKEIIP-UHFFFAOYSA-N	nan	None	Achiral Molecule	LY-2801653 LY2801653 MERESTINIB
Tenalisib		2	Rhizen Pharmaceuticals	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	0	415.1	4.8	96.7	6	2	5	nan	nan		CC[C@@H](c1c(c(=O)c2ccccc2o1)c3cccc(c3)F)Nc4c5c([nH]cn5)ncn4	HDXDQPRPFRKGKZ-INIZCTEOSA-N	nan	None	Single Stereoisomer	TENALISIB
Tarloxotinib		2	Threshold Pharmaceuticals	ChemSpider ChEMBL PubChem FDA SRS			nan	1	679.0	1.6	140.8	9	2	9	nan	EGFR	Tyr	Cn1cnc(c1C[N+](C)(C)C/C=C/C(=O)Nc2cc3c(cn2)ncnc3Nc4ccc(c(c4)Br)Cl)[N+](=O)[O-].[Br-]	WAKIMVYUBWMMHJ-FXRZFVDSSA-N	nan	None	Achiral Molecule	TARLOXOTINIB BROMIDE
Tandutinib		2	Takeda	ChemSpider ChEMBL PubChem DrugBank ZINC FDA SRS BindingDB			nan	2	562.3	5.0	92.3	8	1	10	Investigated for use/treatment in leukemia (myeloid).	FLT3 PDGFD	(*) Tyr	CC(C)Oc1ccc(cc1)NC(=O)N2CCN(CC2)c3c4cc(c(cc4ncn3)OCCCN5CCCCC5)OC	UXXQOJXBIDBUAC-UHFFFAOYSA-N	nan	None	Achiral Molecule	CT 53518 CT-53518 CT53518 MLN-0518 MLN-518 NSC-759851 TANDUTINIB
Talmapimod		2	Scios inc	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'469'	3hub 3zsh	1	1	512.2	4.0	65.9	5	0	5	Investigated for use/treatment in pain (acute or chronic) and rheumatoid arthritis.	MAPK14	CMGC	C[C@@H]1CN([C@H](CN1C(=O)c2cc3c(cc2Cl)n(cc3C(=O)C(=O)N(C)C)C)C)Cc4ccc(cc4)F	ZMELOYOKMZBMRB-DLBZAZTESA-N	nan	None	Single Stereoisomer	SCIO 469 SCIO-469 TALMAPIMOD
Tilpisertib		2	Gilead Sciences	ChemSpider ChEMBL PubChem FDA SRS			nan	2	592.2	6.4	113.5	9	2	7	nan	nan		CC(C)(C)CNC1=C2C=C(C=C(Cl)C2=NC=C1C#N)N[C@@H](C1C=CC=C2C(=O)N(C)C=CC=12)C1=CN(N=N1)C12CC(C1)C2	VFGSKBLZRDRHOI-ZAGPDIDGSA-N	nan	None	Single Stereoisomer	TILPISERTIB
Ilginatinib		2	Nippon Shinyaku	ChemSpider PubChem			nan	0	389.2	4.3	80.6	7	2	6	nan	nan		CC(c1ccc(cc1)F)Nc2cc(cc(n2)Nc3cnccn3)c4cnn(c4)C	UQTPDWDAYHAZNT-UHFFFAOYSA-N	nan	None	Single Stereoisomer	NS-018
Povorcitinib		2	Incyte Corporation	ChemSpider PubChem BindingDB			nan	1	507.2	4.0	102.6	6	2	6	nan	nan		CC1NN=C(C)C=1C1C=NN(C=1)C1(CN(C1)C1C=C(F)C(=CC=1F)C(=O)N[C@@H](C)C(F)(F)F)CC#N	MSGYSFWCPOBHEV-AWEZNQCLSA-N	nan	NaN	NaN	POVORCITINIB
Poziotinib		2	Hanmi Pharmaceutical	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	1	490.1	5.4	76.6	6	1	6	nan	EGFR	Tyr	COc1cc2c(cc1OC3CCN(CC3)C(=O)C=C)c(ncn2)Nc4ccc(c(c4F)Cl)Cl	LPFWVDIFUFFKJU-UHFFFAOYSA-N	nan	None	Achiral Molecule	HM 781-36 HM 781-36B HM-781-36 HM-781-36B HM781-36B NOV-120101 POZIOTINIB POZIOTINIB HYDROCHLORIDE
Tamatinib		2	Rigel Pharmaceuticals	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'585'	3fqs 3piy	1	0	470.2	3.6	128.8	10	3	7	nan	SYK	Tyr	CC1(C(=O)Nc2c(ccc(n2)Nc3c(cnc(n3)Nc4cc(c(c(c4)OC)OC)OC)F)O1)C	NHHQJBCNYHBUSI-UHFFFAOYSA-N	nan	NaN	NaN	R-406 R940406 TAMATINIB
Ralimetinib		2	Eli Lilly	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS			nan	1	420.2	5.6	85.4	5	2	3	nan	MAPK14 MAPK11	CMGC	CC(C)(C)Cn1c2c(ccc(n2)c3c(nc([nH]3)C(C)(C)C)c4ccc(cc4)F)nc1N	XPPBBJCBDOEXDN-UHFFFAOYSA-N	nan	None	Achiral Molecule	LSN-2322600 FREE BASE LSN2322600 FREE BASE LY-2228820 LY2228820 LY22288220 RALIMETINIB
Prexasertib		2	Eli Lilly	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	0	365.2	2.2	134.8	8	3	8	nan	CHEK1 CHEK2	CAMK	COc1cccc(c1c2cc(n[nH]2)Nc3cnc(cn3)C#N)OCCCN	DOTGPNHGTYJDEP-UHFFFAOYSA-N	nan	None	Achiral Molecule	LY2606368 PREXASERTIB
Rabusertib		2	Eli Lilly	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	0	435.1	2.9	97.4	6	3	5	nan	CHEK1	CAMK	Cc1cc(c(cc1Br)NC(=O)Nc2cnc(cn2)C)OC[C@@H]3CNCCO3	SYYBDNPGDKKJDU-ZDUSSCGKSA-N	nan	None	Single Stereoisomer	IC-83 LY-2603618 LY2603618 RABUSERTIB
Onatasertib		2	Celgene	ChemSpider ChEMBL DrugBank ZINC FDA SRS BindingDB			nan	0	397.2	2.5	100.5	7	2	4	nan	nan		CO[C@H]1CC[C@H](N2C(=O)CNc3ncc(-c4ccc(C(C)(C)O)nc4)nc32)CC1	UFKLYTOEMRFKAD-SHTZXODSSA-N	nan	None	Single Stereoisomer	ATG-008 CC-223 ONATASERTIB
Tanzisertib		2	Celgene	ChemSpider ChEMBL DrugBank RCSB PDBe ZINC FDA SRS BindingDB	'KBI'	3tti	1	0	448.2	3.7	97.1	8	3	5	nan	MAPK8	CMGC	c1c(c(c(cc1F)F)Nc2n(c3nc(ncc3n2)N[C@H]4CC[C@@H](CC4)O)[C@@H]5COCC5)F	IBGLGMOPHJQDJB-IHRRRGAJSA-N	nan	None	Single Stereoisomer	CC-930 JNK 930 JNK-930 TANZISERTIB
Telatinib		2	Bayer	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	0	409.1	4.0	102.2	7	2	6	nan	KDR FLT4	Tyr	CNC(=O)c1cc(ccn1)COc2c3c(cco3)c(nn2)Nc4ccc(cc4)Cl	QFCXANHHBCGMAS-UHFFFAOYSA-N	nan	None	Achiral Molecule	BAY 57-9352 BAY-57-9352 BAY-579352 TELATINIB
Danusertib		2	Nerviano Medical Sciences	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'627'	2j50 2v7a 4qo9 5i9z	1	0	474.2	2.6	93.8	6	2	6	nan	AURKA AURKB AURKC	Other	CN1CCN(CC1)c2ccc(cc2)C(=O)Nc3c4c([nH]n3)CN(C4)C(=O)[C@@H](c5ccccc5)OC	XKFTZKGMDDZMJI-HSZRJFAPSA-N	nan	None	Single Stereoisomer	DANUSERTIB PHA-739358
Mavelertinib		2	Pfizer	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	0	415.2	0.7	115.0	10	2	6	nan	nan		Cn1cc(c(n1)OC)Nc2c3c(nc(n2)N4C[C@H]([C@@H](C4)F)NC(=O)C=C)n(cn3)C	JYIUNVOCEFIUIU-GHMZBOCLSA-N	nan	None	Single Stereoisomer	EGFR T790M INHIBITOR PF-06747775 MAVELERTINIB PF-06747775
Edralbrutinib		2	Eternity Bioscience	ChemSpider ChEMBL PubChem FDA SRS BindingDB			nan	0	489.2	3.8	106.2	6	2	4	nan	nan		CC#CC(=O)N1CC[C@@H](n2cc(-c3ccc(Oc4c(F)cccc4F)cc3)c3c(N)n[nH]c(=O)c32)C1	DNPOFZXZJJDQLB-MRXNPFEDSA-N	nan	None	Single Stereoisomer	EDRALBRUTINIB SHR-1459 SHR1459 TG-1701 TG1701
Taletrectinib		2	Daiichi Sankyo	ChemSpider ChEMBL PubChem FDA SRS			nan	0	405.2	4.4	77.5	6	2	7	nan	nan		C[C@@H](N)COc1ccc(-c2cnc3ccc(N[C@H](C)c4cccc(F)c4)nn23)cc1	HEVHTYMYEMEBPX-HZPDHXFCSA-N	nan	None	Single Stereoisomer	DS-6051 TALETRECTINIB
Seralutinib		2	Gilead Sciences	ChemSpider ChEMBL PubChem Guide to Pharmacology FDA SRS			nan	1	469.2	5.3	98.3	7	2	8	nan	nan		COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC	JHJNPOSPVGRIAN-SFHVURJKSA-N	nan	None	Single Stereoisomer	GB-002 GB002 PK-10571 SERALUTINIB
Pelitinib		2	Wyeth	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'93J'	5vcw 7axm	1	1	467.2	5.1	90.3	6	2	8	nan	EGFR ERBB2	Tyr	CCOc1cc2c(cc1NC(=O)/C=C/CN(C)C)c(c(cn2)C#N)Nc3ccc(c(c3)Cl)F	WVUNYSQLFKLYNI-AATRIKPKSA-N	nan	None	Achiral Molecule	EKB-569 PELITINIB WAY-EKB-569
Zapnometinib		2	University of Muenster	ChemSpider ChEMBL PubChem ZINC FDA SRS			nan	0	408.9	4.7	49.3	2	2	3	nan	nan		C1=CC(=C(C=C1I)Cl)NC2=C(C=CC(=C2F)F)C(=O)O	XCNBGWKQXRQKSA-UHFFFAOYSA-N	nan	None	Achiral Molecule	PD-0184264
Voxtalisib		2	Sanofi	ChemSpider ChEMBL PubChem DrugBank ZINC FDA SRS BindingDB			nan	0	270.1	1.1	102.5	6	2	2	nan	PIK3CA MTOR	Atypical	CCn1c2c(cc(c1=O)c3ccn[nH]3)c(nc(n2)N)C	RGHYDLZMTYDBDT-UHFFFAOYSA-N	nan	None	Achiral Molecule	SAR-245409 SAR245409 VOXTALISIB XL-765 XL765
Izencitinib		2	Theravance Biopharma	ChemSpider ChEMBL DrugBank FDA SRS BindingDB			nan	0	402.2	3.7	105.6	7	3	6	nan	nan		Cc1cc(Nc2cc3ncccc3c(N[C@H]3C[C@@H]4CC[C@H](C3)N4CCC#N)n2)n[nH]1	DADAEARVGOQWHV-OSYLJGHBSA-N	nan	None	Single Stereoisomer	IZENCITINIB TD-1473 TD1473
Zorifertinib		2	Astrazeneca	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	0	459.1	4.3	79.8	7	1	4	nan	nan		COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1OC(=O)N1CCN(C)C[C@H]1C	MXDSJQHFFDGFDK-CYBMUJFWSA-N	nan	None	Single Stereoisomer	AZD 3759 AZD-3759 AZD3759 ZORIFERTINIB
Rebastinib	DP-1919;Dp-1919	2	Deciphera Pharmaceuticals	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'919'	3qri 3qrj 5g6v 6cnh 6mwe	2	2	553.2	6.0	123.1	7	3	6	nan	FLT3 TEK KDR LYN BCR ABL1 NTRK1	Atypical Tyr	CC(C)(C)c1cc(n(n1)c2ccc3c(c2)cccn3)NC(=O)Nc4ccc(cc4F)Oc5ccnc(c5)C(=O)NC	WVXNSAVVKYZVOE-UHFFFAOYSA-N	nan	None	Achiral Molecule	DCC-2036 DCC-2036 FREE BASE DP-1919 REBASTINIB
Mivavotinib		2	Takeda	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology FDA SRS BindingDB	'7KG'	5tr6	nan	0	344.2	1.5	97.9	6	3	3	nan	nan		Cn1cc(-c2nc(N[C@@H]3CCCC[C@@H]3N)c(F)c3c2C(=O)NC3)cn1	MJHOMTRKVMKCNE-NWDGAFQWSA-N	nan	None	Single Stereoisomer	MIVAVOTINIB TAK-659F
Decernotinib		2	Vertex Pharmaceuticals	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'VJK'	4yti	1	0	392.2	3.3	95.6	5	3	6	nan	JAK3	Tyr	CC[C@](C)(C(=O)NCC(F)(F)F)Nc1ccnc(n1)c2c[nH]c3c2cccn3	ASUGUQWIHMTFJL-QGZVFWFLSA-N	nan	None	Single Stereoisomer	ADELATINIB DECERNOTINIB VRT-831509 VX-509
Bentamapimod		2	PregLem	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology FDA SRS			nan	0	457.2	4.2	84.2	8	0	7	nan	MAPK8 MAPK9	CMGC	N#CC(c1nc2ccccc2s1)c5nc(OCc3ccc(cc3)CN4CCOCC4)ncc5	XCPPIJCBCWUBNT-UHFFFAOYSA-N	nan	None	Racemic Mixture	AS-602801 BENTAMAPIMOD PGL-5001
Rogaratinib		2	Bayer	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology FDA SRS BindingDB			nan	0	466.2	2.6	107.0	9	2	6	Rogaratinib (BAY-1163877) is a FGFR-selective kinase inhibitor that is being investigated for antineoplastic activity.	nan		Cc1cc2cc(sc2c(c1)OC)c3c(c(n4c3c(ncn4)N)CN5CCNC(=O)C5)COC	HNLRRJSKGXOYNO-UHFFFAOYSA-N	nan	None	Achiral Molecule	BAY-1163877 ROGARATINIB
Roniciclib		2	Bayer	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe ZINC FDA SRS BindingDB	'R0N'	5iev	nan	0	430.1	4.0	108.2	7	3	7	nan	CDK1 CDK2 CDK4 CDK9	CMGC	C[C@H]([C@@H](C)Oc1c(cnc(n1)Nc2ccc(cc2)[S@](=N)(=O)C3CC3)C(F)(F)F)O	UELYDGOOJPRWGF-SRQXXRKNSA-N	nan	None	Single Stereoisomer
Refametinib		2	Bayer	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS	'VRA'	3e8n	nan	1	572.0	3.5	107.9	6	4	9	nan	MAP2K1	STE	COc1cc(c(c(c1NS(=O)(=O)C2(CC2)C[C@@H](CO)O)Nc3ccc(cc3F)I)F)F	RDSACQWTXKSHJT-NSHDSACASA-N	nan	None	Single Stereoisomer	BAY 869766 BAY 8697661 BAY-86-9766 BAY-869766 BAY-8697661 BAY86-9766 RDEA 119 RDEA-119 RDEA119 REFAMETINIB
Acalisib		2	Gilead Sciences	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	0	401.1	3.4	101.4	7	2	4	nan	PIK3CA	Atypical	C[C@@H](c1nc2ccc(cc2c(=O)n1c3ccccc3)F)Nc4c5c(nc[nH]5)ncn4	DOCINCLJNAXZQF-LBPRGKRZSA-N	nan	None	Single Stereoisomer	ACALISIB CAL-120 CAL120 GS-9820 GS9820
Simurosertib		2	Takeda	ChemSpider PubChem			nan	0	341.1	2.8	77.7	5	2	2	nan	nan		Cc1c(c[nH]n1)c2cc3c(s2)c(=O)[nH]c(n3)C4CC5CCN4CC5	XGVXKJKTISMIOW-UHFFFAOYSA-N	nan	None	Single Stereoisomer	TAK931F TAK-931
Seliciclib		2	Cyclacel pharmaceuticals	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'RRC'	1unl 1ygk 2a4l 3ddq	1	0	354.2	3.2	87.9	7	3	8	nan	CDK2 CDK7 CDK9	CMGC	CC[C@H](CO)Nc1nc(NCc2ccccc2)c3ncn(C(C)C)c3n1	BTIHMVBBUGXLCJ-OAHLLOKOSA-N	nan	None	Single Stereoisomer	AL-39256 CYC-202 NSC-701554 R-ROSCOVITINE ROSCOVITIN ROSCOVITINE SELICICLIB
Samotolisib		2	Eli Lilly	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS			nan	0	406.2	3.2	82.2	7	1	5	LY3023414 is a dual inhibitor of phosphoinositide 3-kinase α (PI3Kα) and the serine/threonine kinase mTOR (mechanistic target of rapamycin), with potential antineoplastic activity.	nan		C[C@@H](Cn1c2c3cc(ccc3ncc2n(c1=O)C)c4cc(cnc4)C(C)(C)O)OC	ACCFLVVUVBJNGT-AWEZNQCLSA-N	nan	None	Single Stereoisomer	LY 3023414 LY-3023414 LY3023414 SAMOTOLISIB
Spebrutinib		2	Celgene	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	0	423.2	4.3	97.4	7	3	10	nan	BTK	Tyr	COCCOc1ccc(cc1)Nc2ncc(c(n2)Nc3cccc(c3)NC(=O)C=C)F	KXBDTLQSDKGAEB-UHFFFAOYSA-N	nan	None	Achiral Molecule	AVL-292 BTK INHIBITOR CC-292 CC-292 SPEBRUTINIB
Voruciclib		2	Piramal Enterprises	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	0	469.1	4.3	94.1	6	3	3	nan	CDK4	CMGC	CN1CC[C@H]([C@@H]1CO)c2c(cc(c3c2oc(cc3=O)c4ccc(cc4Cl)C(F)(F)F)O)O	MRPGRAKIAJJGMM-OCCSQVGLSA-N	nan	None	Single Stereoisomer	P1446A-05 VORUCICLIB
Varlitinib		2.5	Array Biopharma	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	1	466.1	5.2	93.5	9	2	6	Investigated for use/treatment in cancer/tumors (unspecified).	EGFR ERBB2	Tyr	C[C@@H]1COC(=N1)Nc2ccc3c(c2)c(ncn3)Nc4ccc(c(c4)Cl)OCc5nccs5	UWXSAYUXVSFDBQ-CYBMUJFWSA-N	nan	None	Single Stereoisomer	AR-00334543 ARRY-334543 ARRY-543 ASLAN-001 ASLAN001 VARLITINIB
Leniolisib		2.5	Novartis	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'9NQ'	5o83	nan	0	450.2	2.9	83.5	7	1	5	nan	nan		CCC(=O)N1CC[C@@H](C1)Nc2c3c(ncn2)CCN(C3)c4cc(c(nc4)OC)C(F)(F)F	MWKYMZXCGYXLPL-ZDUSSCGKSA-N	nan	None	Single Stereoisomer	CDZ-173 FREE BASE CDZ-173-NX CDZ173 FREE BASE CDZ173-NX LENIOLISIB
Cerdulatinib		2.5	Portola pharmaceuticals	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	0	445.2	1.4	133.6	8	3	8	nan	JAK1 SYK	Tyr	CCS(=O)(=O)N1CCN(CC1)c2ccc(cc2)Nc3ncc(c(n3)NC4CC4)C(=O)N	BGLPECHZZQDNCD-UHFFFAOYSA-N	nan	None	Achiral Molecule	CERDULATINIB PRT-062070 PRT-2070 RVT-502
Opaganib		2.5	RedHill Biopharma	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology FDA SRS BindingDB			nan	0	380.2	4.9	42.0	2	1	4	nan	nan		c1cc(ccc1C23CC4CC(C2)CC(C4)(C3)C(=O)NCc5ccncc5)Cl	CAOTVXGYTWCKQE-UHFFFAOYSA-N	nan	None	Achiral Molecule	ABC 294640 ABC-294640 ABC294640 OPAGANIB
Rigosertib		3	Onconova Therapeutics	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'6FS'	5j18 5j2r 5ov7	3	0	451.1	2.8	120.4	8	2	11	nan	PIK3CA PLK1	Atypical Other	COc1ccc(cc1NCC(=O)O)CS(=O)(=O)/C=C/c2c(cc(cc2OC)OC)OC	OWBFCJROIKNMGD-BQYQJAHWSA-N	nan	None	Achiral Molecule	ON 01910 RIGOSERTIB
Abivertinib		3	ACEA Biosciences	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	0	487.2	4.5	98.4	7	3	7	AC0010 is an orally active, irreversible EGFR inhibitor that selectively targets mutated EGFRs, and was designed to overcome T790M-induced resistance in tumours [2]. It may also inhibit BTK, thus offering extended clinical utility [3]. We show the structure for the free base form of the compound.	nan		CN1CCN(CC1)c2ccc(cc2F)Nc3nc4c(cc[nH]4)c(n3)Oc5cccc(c5)NC(=O)C=C	UOFYSRZSLXWIQB-UHFFFAOYSA-N	nan	None	Achiral Molecule	A610 ABIVERTINIB AC-0010 AC0010 ACEA100610 AVITINIB EX-ACEA0010
Ruboxistaurin	Arxxant	3	Eli Lilly	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'LY4'	1uu3 2j2i	nan	0	468.2	3.5	68.5	6	1	2	nan	nan		CN(C)C[C@@H]1CCn2cc(c3c2cccc3)C4=C(c5cn(c6c5cccc6)CCO1)C(=O)NC4=O	ZCBUQCWBWNUWSU-SFHVURJKSA-N	nan	None	Single Stereoisomer	ARXXANT LY-333531 RUBOXISTAURIN
Delgocitinib		3	Japan Tobacco	ChemSpider ChEMBL PubChem BindingDB			nan	0	310.2	1.3	88.9	5	1	2	nan	nan		CC1CN(C12CCN(C2)c3c4cc[nH]c4ncn3)C(=O)CC#N	LOWWYYZBZNSPDT-UHFFFAOYSA-N	nan	None	Single Stereoisomer
Alisertib		3	Millennium Pharmaceuticals	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'A5B'	5ia0	1	2	518.1	5.7	105.9	7	2	6	For the treatment of various forms of cancer.	AURKA	Other	COc1cccc(c1C2=NCc3cnc(nc3-c4c2cc(cc4)Cl)Nc5ccc(c(c5)OC)C(=O)O)F	ZLHFILGSQDJULK-UHFFFAOYSA-N	nan	None	Achiral Molecule	ALISERTIB MLN 8237 MLN-8237 MLN8237
Remibrutinib		3	Novartis	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology FDA SRS BindingDB			nan	1	507.2	4.5	110.4	6	2	9	nan	nan		CC1=C(C=C(C=C1NC(=O)C2=C(C=C(C=C2)C3CC3)F)F)C4=C(C(=NC=N4)N)OCCN(C)C(=O)C=C	CUABMPOJOBCXJI-UHFFFAOYSA-N	nan	NaN	NaN
Motesanib		3	Amgen	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'706'	3efl	2	0	373.2	4.0	78.9	5	3	5	nan	FLT1 KDR FLT4 PDGFRA PDGFRB KIT RET	Tyr	CC1(CNc2c1ccc(c2)NC(=O)c3cccnc3NCc4ccncc4)C	RAHBGWKEPAQNFF-UHFFFAOYSA-N	nan	None	Achiral Molecule	AMG 706 AMG-706 MOTESANIB
Momelotinib		3	Ym Biosciences Australia	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'C87'	6fdz 7nns	nan	0	414.2	3.0	103.2	7	2	6	nan	JAK1 JAK2 JAK3	Tyr	c1cc(ccc1c2ccnc(n2)Nc3ccc(cc3)N4CCOCC4)C(=O)NCC#N	ZVHNDZWQTBEVRY-UHFFFAOYSA-N	nan	None	Achiral Molecule	CYT-0387 CYT-11387 CYT-387 CYT387 GS-0387 MOMELOTINIB
Naquotinib		3	Astellas Pharma	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'8RC'	5y9t 7lg8	nan	1	562.3	2.3	120.2	9	2	9	nan	EGFR	Tyr	CCc1c(nc(c(n1)C(=O)N)Nc2ccc(cc2)N3CCC(CC3)N4CCN(CC4)C)O[C@@H]5CCN(C5)C(=O)C=C	QKDCLUARMDUUKN-XMMPIXPASA-N	nan	None	Single Stereoisomer	ASP-8273 ASP8273 NAQUOTINIB
Selonsertib		3	Gilead Sciences	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'NJV'	6oyt	nan	0	445.2	4.7	90.5	7	1	6	nan	MAP3K5	STE	Cc1cc(c(cc1n2cc(nc2)C3CC3)C(=O)Nc4cccc(n4)c5nncn5C(C)C)F	YIDDLAAKOYYGJG-UHFFFAOYSA-N	nan	None	Achiral Molecule	GS-4997 SELONSERTIB
Alflutinib		3	Allist Pharmaceuticals	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology FDA SRS			nan	1	568.3	4.8	100.4	9	2	11	nan	nan		C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OCC(F)(F)F)nc1N(C)CCN(C)C	GHKOONMJXNWOIW-UHFFFAOYSA-N	nan	None	Achiral Molecule	ALFLUTINIB AST-2818 AST2818 FURMONERTINIB
Semaxanib		3	Sugen	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'X2M'	2x2m	1	0	238.1	3.1	44.9	1	2	1	Investigated for use/treatment in colorectal cancer and lung cancer.	KDR	Tyr	Cc1cc([nH]c1/C=C\2/c3ccccc3NC2=O)C	WUWDLXZGHZSWQZ-WQLSENKSSA-N	nan	None	Achiral Molecule	NSC-696819 SEMAXANIB SEMAXINIB SU-5416 SU005416 SU5416
Savolitinib		3	Astrazeneca	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'V0L'	5lbw 6sde	nan	0	345.1	1.9	91.6	9	0	3	nan	MET	Tyr	C[C@@H](c1ccc2nccn2c1)n3c4c(ncc(n4)c5cnn(c5)C)nn3	XYDNMOZJKOGZLS-NSHDSACASA-N	nan	None	Single Stereoisomer	AZD-6094 AZD6094 HMPL-504 SAVOLITINIB VOLITINIB
Rociletinib		3	Clovis Oncology	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'8JC'	5xdk 5xdl	1	1	555.2	4.8	111.7	8	3	8	nan	EGFR	Tyr	CC(=O)N1CCN(CC1)c2ccc(c(c2)OC)Nc3ncc(c(n3)Nc4cccc(c4)NC(=O)C=C)C(F)(F)F	HUFOZJXAKZVRNJ-UHFFFAOYSA-N	nan	None	Achiral Molecule	AVL-301 CNX-419 CO-1686 CS-1631 ROCILETINIB
Masitinib	Kinavet;Masivet	3	AB Science	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'G65'	5mql 7ju7 7tvx	nan	1	498.2	5.3	73.4	7	2	7	nan	KIT PDGFRA PDGFRB FGFR1 FGFR2 FGFR3	Tyr	Cc1ccc(cc1Nc2nc(cs2)c3cccnc3)NC(=O)c4ccc(cc4)CN5CCN(CC5)C	WJEOLQLKVOPQFV-UHFFFAOYSA-N	nan	None	Achiral Molecule	AB-1010 AB1010 KINAVET MASICAN MASITINIB MASITINIB MESILATE MASITINIB MESYLATE MASITINIB METHANESULFONATE MASIVET MASIVIERA
Evobrutinib		3	Merck	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'MZJ'	6omu	nan	0	429.2	4.4	93.4	6	2	7	nan	BTK	Tyr	C=CC(=O)N1CCC(CC1)CNc2c(c(ncn2)N)c3ccc(cc3)Oc4ccccc4	QUIWHXQETADMGN-UHFFFAOYSA-N	nan	None	Achiral Molecule	EVOBRUTINIB M-2951 MSC-2364447C MSC2364447C
Aumolertinib		3	Jiangsu Hansoh Pharmaceutical	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology FDA SRS			nan	2	525.3	5.3	87.6	8	2	11	nan	nan		CN(C)CCN(C)C1C=C(OC)C(=CC=1NC(=O)C=C)NC1N=C(C=CN=1)C1=CN(C2CC2)C2C=CC=CC=21	DOEOECWDNSEFDN-UHFFFAOYSA-N	nan	None	Unknown
Sitravatinib		3	Mirati Therapeutics	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	2	629.2	6.5	114.5	8	3	12	nan	RET DDR2 NTRK1 NTRK2 NTRK3	Tyr	COCCNCc1ccc(nc1)c2cc3c(s2)c(ccn3)Oc4ccc(cc4F)NC(=O)C5(CC5)C(=O)Nc6ccc(cc6)F	WLAVZAAODLTUSW-UHFFFAOYSA-N	nan	None	Achiral Molecule	MG-516 MG-91516 MGCD-516 MGCD516 SITRAVATINIB
Dovitinib		3	Novartis	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe ZINC FDA SRS BindingDB	'38O'	4tyi 5a46 5am6 5am7 5owq 7akg 7qq6	1	0	392.2	2.5	94.0	5	3	2	nan	FGFR3 VEGFA FGFR1 PDGFRA KIT CSF1R	(*) Tyr	CN1CCN(CC1)c2ccc3c(c2)[nH]c(n3)c4c(c5c(cccc5F)[nH]c4=O)N	PIQCTGMSNWUMAF-UHFFFAOYSA-N	nan	None	Achiral Molecule	CHIR-258 DOVITINIB GFKI-258 NVP-TKI258 TKI-258
Taselisib		3	Hoffmann-La Roche	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'799'	5t8f 8exl	1	0	460.2	3.2	118.7	9	1	5	nan	PIK3CA PIK3CD PIK3CG	Atypical	Cc1nc(n(n1)C(C)C)c2cn3c(n2)-c4ccc(cc4OCC3)c5cnn(c5)C(C)(C)C(=O)N	BEUQXVWXFDOSAQ-UHFFFAOYSA-N	nan	None	Racemic Mixture	GDC-0032 RG-7604 TASELISIB
Losmapimod		3	GlaxoSmithKline	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	0	383.2	3.9	71.1	3	2	5	nan	MAPK14 MAPK11 MAPK13 MAPK12	CMGC	Cc1c(cc(cc1F)C(=O)NC2CC2)c3ccc(cn3)C(=O)NCC(C)(C)C	KKYABQBFGDZVNQ-UHFFFAOYSA-N	nan	None	Achiral Molecule	FTX-1821 FTX1821 GSK-AHAB GSKAHAB GW-856553 GW-856553X GW856553 GW856553X LOSMAPIMOD
Tesevatinib		3	Kadmon Corporation	ChemSpider ChEMBL DrugBank ZINC FDA SRS BindingDB			nan	1	490.1	5.8	59.5	6	1	6	nan	EGFR ERBB2 KDR FLT4 EPHB4	Tyr	CN1C[C@H]2C[C@H](C[C@H]2C1)COc3cc4c(cc3OC)c(ncn4)Nc5ccc(c(c5F)Cl)Cl	HVXKQKFEHMGHSL-QKDCVEJESA-N	nan	None	Racemic Mixture	EXEL-7647 KD-019 KD-020 KD019 TESEVATINIB XL-647 XL647
Saracatinib		3	Astrazeneca	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'H8H'	2h8h 4qmx 5vcx 5vd3 6zgc	1	1	541.2	3.9	90.4	10	1	8	nan	SRC ABL1	Tyr	CN1CCN(CC1)CCOc2cc3c(c(c2)OC4CCOCC4)c(ncn3)Nc5c(ccc6c5OCO6)Cl	OUKYUETWWIPKQR-UHFFFAOYSA-N	nan	None	Achiral Molecule	AZ-10353926 AZD-0530 AZD0530 SARACATINIB
Peficitinib		3	Astellas Pharma	ChemSpider ChEMBL RCSB PDBe ZINC	'9T6'	6aah 6aaj 6aak 6aam	nan	0	326.2	2.0	104.0	4	4	3	nan	JAK1 JAK2 JAK3 TYK2	Tyr	c1c[nH]c2c1c(c(cn2)C(=O)N)N[C@@H]3[C@@H]4C[C@@H]5C[C@H]3C[C@@](C5)(C4)O	DREIJXJRTLTGJC-ZKVNVPQCSA-N	nan	None	Racemic Mixture
Tolebrutinib		3	Principia Biopharma	ChemSpider ChEMBL PubChem Guide to Pharmacology FDA SRS			nan	0	455.2	3.9	95.4	7	1	5	nan	nan		C=CC(=O)N1CCCC(C1)N2C3=C(C(=NC=C3)N)N(C2=O)C4=CC=C(C=C4)OC5=CC=CC=C5	KOEUOFPEZFUWRF-LJQANCHMSA-N	nan	None	Single Stereoisomer	TOLEBRUTINIB
Linsitinib		3	Osi Pharmaceuticals	ChemSpider ChEMBL DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	0	421.2	4.8	89.3	6	2	3	nan	IGF1R	Tyr	C[C@]1(C[C@@H](C1)c2n3c(c(ncc3)N)c(n2)c4cc5nc(ccc5cc4)c6ccccc6)O	PKCDDUHJAFVJJB-VLZXCDOPSA-N	nan	None	Single Stereoisomer	ASP-7487 LINSITINIB OSI-906 OSI-906AA
Rilzabrutinib		3	Principia Biopharma	ChemSpider ChEMBL PubChem RCSB PDBe Guide to Pharmacology ZINC FDA SRS	'R1L'	7l5o 7l5p	nan	2	665.3	4.4	138.7	11	1	8	nan	nan		CC(C)(/C=C(\C#N)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)C1)N1CCN(C2COC2)CC1	LCFFREMLXLZNHE-GBOLQPHISA-N	nan	None	Single Stereoisomer	PRN-1008 PRN1008 RILZABRUTINIB
Radotinib		3	Il-Yang Pharmaceutical	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS			nan	2	530.2	5.8	110.5	8	2	6	Radotinib is indicated for the treatment of different types of cancer, most notably Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) with resistance or intolerance of other Bcr-Abl tyrosine-kinase inhibitors, such as patients resistant or intolerant to imatinib.	ABL1 PDGFRB	Tyr	Cc1ccc(cc1Nc2nccc(n2)c3cnccn3)C(=O)Nc4cc(cc(c4)n5cc(nc5)C)C(F)(F)F	DUPWHXBITIZIKZ-UHFFFAOYSA-N	nan	None	Achiral Molecule	IY5511 RADOTINIB
Lestaurtinib		3	Cephalon	ChemSpider ChEMBL PubChem RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'2V9'	4otg 5wnj	nan	0	439.2	3.5	88.7	6	3	1	nan	FLT3	Tyr	C[C@@]12[C@](C[C@@H](O1)n3c4ccccc4c5c3c6n2c7ccccc7c6c8c5C(=O)NC8)(CO)O	UIARLYUEJFELEN-LROUJFHJSA-N	nan	None	Single Stereoisomer	A-154475 A-154475.0 CEP-701 KT-555 KT-5555 KT5555 LESTAURTINIB SP-924 SP924 SPM-924
Surufatinib		3	Hutchison MediPharma	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS			nan	0	480.2	3.8	112.2	7	3	10	nan	nan		Cc1cc2cc(ccc2[nH]1)Oc3ccnc(n3)Nc4cccc(c4)CS(=O)(=O)NCCN(C)C	TTZSNFLLYPYKIL-UHFFFAOYSA-N	nan	None	Achiral Molecule	HMPL-012 SULFATINIB SURUFATINIB
Tivantinib		3	Daiichi Sankyo	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'TIV'	5cb4	nan	0	369.1	3.6	66.9	3	2	2	nan	MET	Tyr	c1ccc2c(c1)c(c[nH]2)[C@H]3[C@@H](C(=O)NC3=O)c4cn5c6c4cccc6CCC5	UCEQXRCJXIVODC-PMACEKPBSA-N	nan	None	Single Stereoisomer	ARQ 197 ARQ-197 TIVANTINIB
Dinaciclib		3	Schering-Plough	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	0	396.2	2.3	92.6	7	2	7	nan	CDK4 CDK6 BRDT	(*) CMGC	CCc1cnn2c1nc(cc2NCc3ccc[n+](c3)[O-])N4CCCC[C@H]4CCO	PIMQWRZWLQKKBJ-SFHVURJKSA-N	nan	None	Single Stereoisomer	DINACICLIB MK-7965 SCH 727965 SCH-727965
Linifanib		3	Abbott Laboratories	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	0	375.1	4.9	95.8	3	4	3	nan	FLT3 CSF1R KDR	Tyr	Cc1ccc(c(c1)NC(=O)Nc2ccc(cc2)c3cccc4c3c(n[nH]4)N)F	MPVGZUGXCQEXTM-UHFFFAOYSA-N	nan	None	Achiral Molecule	A-741439 ABT-869 AL-39324 LINIFANIB RG-3635
Pyrotinib		3	Hengrui Therapeutics	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	2	582.2	6.5	112.4	8	2	10	nan	EGFR ERBB2	Tyr	CCOc1cc2c(cc1NC(=O)/C=C/[C@H]3CCCN3C)c(c(cn2)C#N)Nc4ccc(c(c4)Cl)OCc5ccccn5	SADXACCFNXBCFY-IYNHSRRRSA-N	nan	None	Single Stereoisomer
Fenebrutinib		3	Genentech	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'9AJ'	5vfi	nan	2	664.3	3.6	121.0	11	2	7	nan	nan		C[C@H]1CN(CCN1c2ccc(nc2)Nc3cc(cn(c3=O)C)c4ccnc(c4CO)N5CCn6c(cc7c6CC(C7)(C)C)C5=O)C8COC8	WNEODWDFDXWOLU-QHCPKHFHSA-N	nan	None	Single Stereoisomer	FENEBRUTINIB G-02599853 G02599853 GDC-0853 RG-7845 RG7845 RO-7010939 RO7010939
Itacitinib		3	Incyte Corporation	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	1	553.2	3.6	119.6	8	1	5	nan	JAK1	Tyr	c1cnc-2[nH]cnc(c12)c3cnn(c3)C4(CN(C4)C5CCN(CC5)C(=O)c6ccnc(c6F)C(F)(F)F)CC#N	KTBSXLIQKWEBRB-UHFFFAOYSA-N	nan	None	Achiral Molecule	INCB-039110 INCB-39110 INCB039110 ITACITINIB
Vatalanib		3	Novartis	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	1	346.1	5.0	50.7	4	1	4	Used in combination with first- and second-line chemotherapy for the treatment of metastatic colorectal cancer and non-small cell lung cancer (NSCLC).	FLT1 KDR FLT4	Tyr	c1ccc2c(c1)c(nnc2Nc3ccc(cc3)Cl)Cc4ccncc4	YCOYDOIWSSHVCK-UHFFFAOYSA-N	nan	None	Achiral Molecule	BAY-86-5127 CGP-79787 K-222584 NVP-PTK787 PTK-787 PTK787 VATALANIB VATALANIB SUCCINATE ZK-222584 ZK222584
Lazertinib		3	Genosco	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology FDA SRS			nan	1	554.3	4.1	109.7	10	2	10	Lazertinib (YH-25448, GNS-1480) is an inhibitor of the aberrant activity of EGFR mutant kinases, that was originally developed by Yuhan Corporation for antineoplastic potential in cancers with (acquired) resistance to existing EGFR tyrosine kinase inhibitors, in particular for EGFR mutation positive, advanced non-small cell lung cancer (NSCLC). In addition to predicted efficacy for the treatment of primary lung and extracranial lesions, lazertinib is expected to be beneficial for NSCLC brain metastases as it is able to cross the blood brain barrier.	nan		CN(C)Cc1cn(nc1c2ccccc2)c3ccnc(n3)Nc4cc(c(cc4OC)N5CCOCC5)NC(=O)C=C	RRMJMHOQSALEJJ-UHFFFAOYSA-N	nan	None	Achiral Molecule	C-18112003-G GNS-1480 GNS1480 JNJ-73841937-AAA LAZERTINIB YH-25448 YH25448
Olverembatinib		3	Guangzhou Institutes of Biomedicine and Health	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	1	532.2	4.7	77.2	5	2	4	nan	nan		Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2[nH]ncc2c1	TZKBVRDEOITLRB-UHFFFAOYSA-N	nan	None	Achiral Molecule	D-824 D-824 DIMESYLATE GZD-824 GZD-824 DIMESYLATE HQP-1351 HQP-1351 DIMESYLATE HQP1351 HQP1351 DIMESYLATE OLVEREMBATINIB OLVEREMBATINIB DIMESYLATE
Ensartinib		3	Xcovery	ChemSpider ChEMBL PubChem DrugBank ZINC FDA SRS BindingDB			nan	1	560.2	4.7	122.5	7	3	6	nan	ALK	Tyr	C[C@@H]1CN(C[C@@H](N1)C)C(=O)c2ccc(cc2)NC(=O)c3cc(c(nn3)N)O[C@H](C)c4c(ccc(c4Cl)F)Cl	GLYMPHUVMRFTFV-QLFBSQMISA-N	nan	None	Single Stereoisomer	ENSARTINIB X-396
Ripasudil		3	Kowa Pharmaceutical	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	0	323.1	1.7	62.3	4	1	2	nan	nan		C[C@H]1CNCCCN1S(=O)(=O)c2cccc3c2c(cnc3)F	QSKQVZWVLOIIEV-NSHDSACASA-N	nan	None	Single Stereoisomer	RIPASUDIL
Volasertib		3	Boehringer Ingelheim	ChemSpider ChEMBL DrugBank RCSB PDBe Guide to Pharmacology FDA SRS BindingDB	'IBI'	3fc2 5v67 5vbr 7lak 7lej 7n7n	1	1	618.4	4.3	106.2	9	2	10	nan	PLK1	Other	CC[C@H]1N(c2nc(ncc2N(C1=O)C)Nc3c(cc(cc3)C(=O)N[C@H]4CC[C@@H](CC4)N5CCN(CC5)CC6CC6)OC)C(C)C	SXNJFOWDRLKDSF-STROYTFGSA-N	nan	None	Single Stereoisomer	BI 6727 BI-6727 VOLASERTIB
Alvocidib		3	Sanofi	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'CPB'	1c8k 1e1y 3blr 3ebp 4o71	nan	0	401.1	3.3	94.1	6	3	2	Investigated for use/treatment in esophageal cancer, leukemia (lymphoid), lung cancer, liver cancer, and lymphoma (unspecified).	nan		CN1CC[C@@H]([C@@H](C1)O)c2c(cc(c3c2oc(cc3=O)c4ccccc4Cl)O)O	BIIVYFLTOXDAOV-YVEFUNNKSA-N	nan	None	Single Stereoisomer	ALVOCIDIB ALVOCIDIB FREEBASE FLAVOPIRIDOL HL 275 HL-275 HMR 1275 HMR-1275 L 86 8275 L-868275 L86-8275 MDL 107,826A MDL-107826A NSC-649890
Brivanib		3	Bristol Myers Squibb	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	0	370.1	3.5	84.7	6	2	5	nan	KDR	Tyr	Cc1cc2c([nH]1)ccc(c2F)Oc3c4c(c(cn4ncn3)OC[C@@H](C)O)C	WCWUXEGQKLTGDX-LLVKDONJSA-N	nan	None	Single Stereoisomer	BMS-540215 BRIVANIB
Ipatasertib		3	Hoffmann-La Roche	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'0RF'	4ekl	1	0	457.2	3.1	81.6	6	2	6	nan	AKT1 AKT2 AKT3	AGC	C[C@@H]1C[C@H](c2c1c(ncn2)N3CCN(CC3)C(=O)[C@H](CNC(C)C)c4ccc(cc4)Cl)O	GRZXWCHAXNAUHY-NSISKUIASA-N	nan	None	Single Stereoisomer	GDC-0068 IPATASERTIB RG-7440 RG7440
Buparlisib		3	Novartis	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'SD5'	3sd5 5m7e 7r26	1	0	410.2	1.8	89.6	8	1	3	nan	PIK3CA	Atypical	c1c(c(cnc1N)c2cc(nc(n2)N3CCOCC3)N4CCOCC4)C(F)(F)F	CWHUFRVAEUJCEF-UHFFFAOYSA-N	nan	None	Achiral Molecule	BKM-120 BKM-120NX BKM120-NX BUPARLISIB NVP-BKM-120 NVP-BKM120
Barasertib		3	Astrazeneca	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	1	587.2	3.6	174.8	9	5	15	nan	AURKB	Other	CCN(CCCOc1ccc2c(c1)ncnc2Nc3cc(n[nH]3)CC(=O)Nc4cccc(c4)F)CCOP(=O)(O)O	GBJVVSCPOBPEIT-UHFFFAOYSA-N	nan	None	Achiral Molecule	AZD 1152 AZD-1152 AZD1152 BARASERTIB BARASERTIB (WHO-DD)
Quizartinib		3	Ambit Biosciences	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'P30'	4rt7 4xuf	2	2	560.2	5.9	106.2	9	2	7	nan	FLT3 CSF1R KIT	Tyr	CC(C)(C)c1cc(no1)NC(=O)Nc2ccc(cc2)c3cn4c5ccc(cc5sc4n3)OCCN6CCOCC6	CVWXJKQAOSCOAB-UHFFFAOYSA-N	nan	None	Achiral Molecule	AC-010220 AC-220 AC010220 AC220 ASP-2689 QUIZARTINIB
Inavolisib		3	Genentech	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'X3N'	8exv	nan	0	407.1	2.9	112.7	7	3	5	nan	nan		C[C@@H](C(=N)O)Nc1ccc-2c(c1)OCCn3c2nc(c3)N4[C@@H](COC4=O)C(F)F	SGEUNORSOZVTOL-CABZTGNLSA-N	nan	None	Single Stereoisomer	GDC-0077 GDC0077 INAVOLISIB RG-6114 RG6114 RO-7113755 RO7113755
Brivanib alaninate		3	Bristol Myers Squibb	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS			nan	0	441.2	3.4	116.8	8	2	7	nan	nan		Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](C)N)c(C)c34)ccc2[nH]1	LTEJRLHKIYCEOX-OCCSQVGLSA-N	nan	None	Single Stereoisomer	BMS-582664 BMS-582664-02 BRIVANIB ALANINATE BRIVANIB L-ALANINE ESTER
Ritlecitinib		3	Pfizer	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	0	285.2	1.9	73.9	4	2	3	nan	nan		C=CC(=O)N1C[C@H](Nc2ncnc3[nH]ccc23)CC[C@@H]1C	CBRJPFGIXUFMTM-WDEREUQCSA-N	nan	None	Single Stereoisomer	PF-06651600 RITLECITINIB
Nazartinib		3	Novartis	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	0	494.2	4.3	83.4	6	1	6	nan	nan		Cc1cc(ccn1)C(=O)Nc2nc3cccc(c3n2[C@@H]4CCCCN(C4)C(=O)/C=C/CN(C)C)Cl	IOMMMLWIABWRKL-WUTDNEBXSA-N	nan	None	Single Stereoisomer	EGF-816 EGF816 NAZARTINIB NVP-EGF816-NX
Zandelisib		3	Pathway Therapeutics	ChemSpider ChEMBL PubChem Guide to Pharmacology ZINC FDA SRS			nan	2	576.3	5.2	84.2	9	1	8	nan	nan		CN1CCC(c2ccccc2CC(C)(C)Nc2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1	WPFUFWIHMYZXSF-UHFFFAOYSA-N	nan	None	Achiral Molecule	ACC-524 ME-401 PW-143 PWT-143 PWT143 ZANDELISIB
Famitinib		3	Jiangsu Hengrui Medicine	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	0	410.2	3.3	68.4	3	2	6	nan	KIT KDR FLT4 PDGFRA PDGFRB FLT1 FLT3	Tyr	CCN(CC)CCN1CCc2c(c(c([nH]2)/C=C\3/c4cc(ccc4NC3=O)F)C)C1=O	GKEYKDOLBLYGRB-LGMDPLHJSA-N	nan	None	Achiral Molecule	FAMITINIB SHR-1020 SHR1020
Canertinib		3	Pfizer	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	0	485.2	4.4	88.6	7	2	9	Investigated for use/treatment in breast cancer and lung cancer.	EGFR	Tyr	C=CC(=O)Nc1cc2c(cc1OCCCN3CCOCC3)ncnc2Nc4ccc(c(c4)Cl)F	OMZCMEYTWSXEPZ-UHFFFAOYSA-N	nan	None	Achiral Molecule	CANERTINIB CI-1033
Parsaclisib		3	Incyte Corporation	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology FDA SRS BindingDB			nan	0	432.1	3.1	107.9	7	2	5	Parsaclisib (INCB050465) is a PI3Kδ inhibitor that was developed by Incyte Corporation as an antineoplastic and immunomodulatory agent, as claimed in their patent WO2014134426A1 [1]. The chemical structure is one of those claimed in patent WO2013033569A1, but it is not clear which example it is from a mixture of diastereoisomers 345-348 (although 347 and 348 had the highest inhibitory potency vs. PI3Kδ and 347 was tested in vivo [2].	nan		CCOc1c(cc(c(c1[C@H]2CC(=O)NC2)F)Cl)[C@H](C)n3c4c(c(n3)C)c(ncn4)N	ZQPDJCIXJHUERQ-QWRGUYRKSA-N	nan	None	Single Stereoisomer	INCB-050465 INCB050465 PARSACLISIB
Simotinib		3	Advenchen Laboratories	ChemSpider ChEMBL PubChem Guide to Pharmacology ZINC FDA SRS			nan	1	500.2	4.4	78.0	8	1	7	nan	EGFR	Tyr	COc1cc2c(cc1OCCN3CC4(CC4)C5(C3)OCCO5)c(ncn2)Nc6ccc(c(c6)Cl)F	OXWUWXCJDBRCCG-UHFFFAOYSA-N	nan	None	Achiral Molecule	SIM-6802 SIMOTINIB
Pirtobrutinib		3	Loxo Oncology	ChemSpider ChEMBL PubChem FDA SRS			nan	0	479.2	3.4	125.3	6	3	7	nan	nan		COc1ccc(F)cc1C(=O)NCc1ccc(-c2nn([C@@H](C)C(F)(F)F)c(N)c2C(N)=O)cc1	FWZAWAUZXYCBKZ-NSHDSACASA-N	nan	None	Single Stereoisomer	LOXO-305 LY-3527727 LY3527727 PIRTOBRUTINIB RXC-005
Capivasertib		3	Astrazeneca	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'0XZ'	4gv1	nan	0	428.2	2.1	120.2	6	4	6	nan	AKT1	AGC	c1cc(ccc1[C@H](CCO)NC(=O)C2(CCN(CC2)c3c4cc[nH]c4ncn3)N)Cl	JDUBGYFRJFOXQC-KRWDZBQOSA-N	nan	None	Single Stereoisomer	AZC5363 AZD 5363 AZD-5363 AZD5363 CAPIVASERTIB
Gedatolisib		3	Pfizer	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'VL1'	7jwe	nan	1	615.3	3.0	128.3	10	2	7	nan	PIK3CA PIK3CB PIK3CG PIK3CD MTOR	Atypical	CN(C)C1CCN(CC1)C(=O)c2ccc(cc2)NC(=O)Nc3ccc(cc3)c4nc(nc(n4)N5CCOCC5)N6CCOCC6	DWZAEMINVBZMHQ-UHFFFAOYSA-N	nan	None	Achiral Molecule	GEDATOLISIB PF-05212384 PKI-587
Crenolanib		3	Arog Pharmaceuticals	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'6T2'	5lby 6bqp 6joi 6joj	1	0	443.2	3.9	78.4	7	1	5	nan	FLT3 PDGFRA PDGFRB	Tyr	CC1(COC1)COc2ccc3c(c2)ncn3c4ccc5cccc(c5n4)N6CCC(CC6)N	DYNHJHQFHQTFTP-UHFFFAOYSA-N	nan	None	Achiral Molecule	ARO 002 ARO-002 CP 868596 CP-868,596 CP-868596 CRENOLANIB
Fruquintinib		3	Hutchison MediPharma	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS			nan	0	393.1	3.9	95.7	7	1	5	nan	FLT1 KDR FLT4	Tyr	Cc1c(c2ccc(cc2o1)Oc3c4cc(c(cc4ncn3)OC)OC)C(=O)NC	BALLNEJQLSTPIO-UHFFFAOYSA-N	nan	None	Achiral Molecule	FRUQUINTINIB HMPL-013 HMPL013
Cediranib	Recentin	3	Astrazeneca	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	1	450.2	5.2	72.5	6	1	8	For the treatment of liver cancer, advanced non-small cell lung cancer (NSCLC), advanced colorectal cancer (CRC) and other solid tumors.	KDR	Tyr	Cc1cc2c([nH]1)ccc(c2F)Oc3c4cc(c(cc4ncn3)OCCCN5CCCC5)OC	XXJWYDDUDKYVKI-UHFFFAOYSA-N	nan	None	Achiral Molecule	AZD-2171 AZD2171 CEDIRANIB RECENTIN ZD-2171
Orelabrutinib	Innobruka	3	InnoCare Pharma	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology FDA SRS BindingDB			nan	0	427.2	4.5	85.5	4	1	6	nan	nan		C=CC(=O)N1CCC(CC1)C1=CC=C(C(N)=O)C(=N1)C1C=CC(=CC=1)OC1C=CC=CC=1	MZPVEMOYADUARK-UHFFFAOYSA-N	nan	None	Achiral Molecule	ICP-022 INNOBRUKA ORELABRUTINIB
Dactolisib		3	Novartis	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	1	469.2	5.9	76.5	6	0	3	nan	PIK3CA PIK3CB PIK3CG PIK3CD MTOR	Atypical	CC(C)(C#N)c1ccc(cc1)n2c3c4cc(ccc4ncc3n(c2=O)C)c5cc6ccccc6nc5	JOGKUKXHTYWRGZ-UHFFFAOYSA-N	nan	None	Achiral Molecule	BEZ-235 BEZ235 DACTOLISIB NSC-751249 NVP-BEZ-235 NVP-BEZ235 NVP-BEZ235-NX RTB-101 RTB101
Enzastaurin	Kinenza	3	Eli Lilly	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	1	515.2	4.9	72.2	6	1	5	nan	nan		Cn1cc(c2c1cccc2)C3=C(C(=O)NC3=O)c4cn(c5c4cccc5)C6CCN(CC6)Cc7ccccn7	AXRCEOKUDYDWLF-UHFFFAOYSA-N	nan	None	Achiral Molecule	DB-102 DB102 ENZASTAURIN KINENZA LY-317615 LY317615
Chiauranib		3	Chipscreen Biosciences	ChemSpider PubChem DrugBank Guide to Pharmacology FDA SRS			nan	1	435.2	6.0	86.5	5	2	5	nan	nan		COC1=CC=C2C(=CC=NC2=C1)OC1=CC2=CC=CC(C(=O)NC3=CC=CC=C3N)=C2C=C1	BRKWREZNORONDU-UHFFFAOYSA-N	nan	None	Single Stereoisomer	CHIAURANIB CAPSULES CS-2164 CS2164
Orantinib		3	Pfizer	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'SU6'	4jlc 5yvc	1	0	310.1	3.1	82.2	2	3	4	nan	KDR PDGFRB FGFR1	Tyr	Cc1c(c([nH]c1/C=C\2/c3ccccc3NC2=O)C)CCC(=O)O	NHFDRBXTEDBWCZ-ZROIWOOFSA-N	nan	None	Achiral Molecule	NSC-702827 ORANTINIB SU-6668 TSU-68
Encorafenib	Braftovi	4	Novartis	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	1	539.2	3.9	140.1	9	3	9	On June 27, 2018, the Food and Drug Administration approved encorafenib and binimetinib in combination patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.	BRAF	TKL	C[C@@H](CNc1nccc(n1)c2cn(nc2c3cc(cc(c3F)NS(=O)(=O)C)Cl)C(C)C)NC(=O)OC	CMJCXYNUCSMDBY-ZDUSSCGKSA-N	2018	US-8501758-B2	Single Stereoisomer	BRAFTOVI ENCORAFENIB LGX-818 LGX818 NVP-LGX-818-NXA NVP-LGX818 NVP-LGX818-NXA	Y
Mobocertinib		4	Takeda	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology FDA SRS BindingDB			nan	2	585.3	5.1	113.8	10	2	12	On September 2021, FDA approved mobocertinib to treat ocally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations	nan		C=CC(=O)Nc1cc(Nc2ncc(C(=O)OC(C)C)c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C	AZSRSNUQCUDCGG-UHFFFAOYSA-N	2021	None	Achiral Molecule	AP-32788 AP32788 MOBOCERTINIB TAK-788	Y
Entrectinib	Rozlytrek	4	Ignyta	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'YMX'	5fto 5kvt	1	2	560.3	5.0	85.5	6	3	7	On august 2019, FDA approved entrectinib to treat adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive and to treat adult and pediatric patients 12 years of age and older with solid tumors	NTRK1 NTRK2 NTRK3 ROS1 ALK	Tyr	CN1CCN(CC1)c2ccc(c(c2)NC3CCOCC3)C(=O)Nc4c5cc(ccc5[nH]n4)Cc6cc(cc(c6)F)F	HAYYBYPASCDWEQ-UHFFFAOYSA-N	2019	US-8299057-B2	Achiral Molecule	ENTRECTINIB NMS-E628 ROZLYTREK RXDX-101	Y
Futibatinib		4	Taiho Pharmaceutical	ChemSpider ChEMBL PubChem BindingDB			nan	0	418.2	1.8	108.4	8	1	4	On September 2022, FDA approved futibatinib to treat intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements	FGFR1 FGFR2 FGFR3 FGFR4	Tyr	COc1cc(cc(c1)OC)C#Cc2c3c(ncnc3n(n2)C4CCN(C4)C(=O)C=C)N	KEIPNCCJPRMIAX-UHFFFAOYSA-N	2022	None	Single Stereoisomer		Y
Erlotinib	Tarceva	4	Osi Pharmaceuticals	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'AQ4'	1m17 4hjo 6dwn	1.5	0	393.2	3.4	74.7	7	1	10	For the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Also for use, in combination with gemcitabine, as the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.	EGFR NR1I2	(*) Tyr	COCCOc1cc2c(cc1OCCOC)ncnc2Nc3cccc(c3)C#C	AAKJLRGGTJKAMG-UHFFFAOYSA-N	2004	None	Achiral Molecule	CP-358,774 CP-358774 CP-35877401 ERLOTINIB OSI-774 R-1415 RG-1415 RO-508231 TARCEVA	Y
Fasudil		4	Asahi Kasei Pharma Corp	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'M77'	1q8w 2esm 2f2u 2gni 3tku 5lcp 5nw8 5o0e 5ok3 5vef 6em2 6emb 6ers 6erw 6i2a 6i2c 6yna	nan	0	291.1	1.2	62.3	4	1	2	Fasudil is a potent inhibitor of the Rho-kinases ROCK1 and ROCK2.	nan		c1cc2cnccc2c(c1)S(=O)(=O)N3CCCNCC3	NGOGFTYYXHNFQH-UHFFFAOYSA-N	nan	None	Achiral Molecule	AT 877 AT-877 FASUDIL HA 1077 HA-1077 NSC-759827 ZK-258594	N
Tucatinib	Tukysa	4	Array BioPharma	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	1	480.2	5.1	110.9	10	2	5	On April 2020, FDA approved tucatinib to treat advanced unresectable or metastatic HER2-positive breast cancer.	ERBB2	Tyr	Cc1cc(ccc1Oc2ccn3c(c2)ncn3)Nc4c5cc(ccc5ncn4)NC6=NC(CO6)(C)C	SDEAXTCZPQIFQM-UHFFFAOYSA-N	2020	US-7452895-B2	Achiral Molecule	ARRY-380 IRBINITINIB ONT-380 TUCATINIB TUKYSA	Y	230
Erdafitinib	Balversa	4	Janssen	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'5SF'	5ew8	1	0	446.2	4.2	77.3	8	1	9	On april 2019, FDA approved erdafitinib to treat adult patients with locally advanced or metastatic bladder cancer	FGFR1	Tyr	CC(C)NCCN(c1ccc2c(c1)nc(cn2)c3cnn(c3)C)c4cc(cc(c4)OC)OC	OLAHOMJCDNXHFI-UHFFFAOYSA-N	2019	US-8895601-B2	Achiral Molecule	BALVERSA ERDAFITINIB JNJ-42756493	Y
Trilaciclib		4	G1 Therapeutics	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	0	446.3	2.7	91.2	8	2	3	On February 2021, FDA approved trilaciclib to mitigate chemotherapy-induced myelosuppression in adult patients with small cell lung cancer	CDK4 CDK6	CMGC	CN1CCN(CC1)c2ccc(nc2)Nc3ncc4cc5n(c4n3)C6(CCCCC6)CNC5=O	PDGKHKMBHVFCMG-UHFFFAOYSA-N	2021	US-8598197-B2;US-8598186-B2	Achiral Molecule	G1T28 TRILACICLIB	Y
Pralsetinib	Gavreto	4	Blueprint Medicines	ChemSpider ChEMBL DrugBank RCSB PDBe FDA SRS	'Q4J'	7du9 7ju5	nan	1	533.3	4.2	135.5	9	3	8	Pralsetinib, also known as BLU-667, is a highly potent, selective, next generation RET inhibitor. BLU-667 is a potent and selective inhibitor of RET mutations, fusions, and predicted resistant mutants. RET fusions are key drivers of multiple cancers, including lung and thyroid cancer, and our research suggests that RET also plays a key role in some colon and breast cancers. By simultaneously targeting the primary driver and predicted resistant mutants that render cancer cells insensitive to treatment with currently approved drugs	nan		Cc1[nH]nc(c1)Nc2nc(nc(c2)C)[C@H]3CC[C@@](CC3)(OC)C(=O)N[C@H](c4cnc(cc4)n5ncc(c5)F)C	GBLBJPZSROAGMF-BATDWUPUSA-N	2020	US-10030005-B2	Single Stereoisomer	RO7499790 BLU-667 GAVRETO (US RG6396 X581238 BLU123244 X-581238 GAVRETO BLU-123244	Y
Palbociclib	Ibrance	4	Pfizer	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'LQQ'	2euf 5l2i 7n7o	1	0	447.2	3.0	105.0	9	2	5	Palbociclib is indicated in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease. This indication is approved under accelerated approval based on progression-free survival (PFS). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.	CDK4 CDK6	CMGC	Cc1c2cnc(nc2n(c(=O)c1C(=O)C)C3CCCC3)Nc4ccc(cn4)N5CCNCC5	AHJRHEGDXFFMBM-UHFFFAOYSA-N	2015	US-6936612-B2	Achiral Molecule	IBRANCE PALBOCICLIB PD-0332991	Y	263-266 ºC
Pemigatinib	Pemazyre	4	Incyte Corporation	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology FDA SRS BindingDB	'8ZF'	7wcl	nan	0	487.2	3.7	83.2	6	1	6	On April 2020, FDA approved pemigatinib to treat certain patients with cholangiocarcinoma, a rare form of cancer that forms in bile ducts.	nan		CCN1c2c3cc([nH]c3ncc2CN(C1=O)c4c(c(cc(c4F)OC)OC)F)CN5CCOCC5	HCDMJFOHIXMBOV-UHFFFAOYSA-N	2020	US-9611267-B2	Achiral Molecule	FGFR INHIBITOR INCB054828 INCB-054828 INCB054828 PEMAZYRE PEMIGATINIB	Y
Pexidartinib	Turalio	4	Daiichi Sankyo	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'P31'	4r7h 7khg	2	1	417.1	5.2	66.5	4	2	5	On august 2019, FDA approved pexidartinib to treat adult patients with symptomatic tenosynovial giant cell tumor	FLT3 KIT CSF1R	Tyr	c1cc(ncc1Cc2c[nH]c3c2cc(cn3)Cl)NCc4ccc(nc4)C(F)(F)F	JGWRKYUXBBNENE-UHFFFAOYSA-N	2019	US-7893075-B2	Achiral Molecule	CML-261 PEXIDARTINIB PLX-3397 PLX3397	Y
Osimertinib	Tagrisso	4	Astrazeneca	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'YY3'	4zau 6jwl 6jx0 6jx4 6jxt 6lud 7jxm 7jxp 7jxw 7k1h	1	0	499.3	4.5	87.6	8	2	10	Osimertinib is indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA- approved test, who have progressed on or after EGFR-TKI therapy.	EGFR	Tyr	Cn1cc(c2c1cccc2)c3ccnc(n3)Nc4cc(c(cc4OC)N(C)CCN(C)C)NC(=O)C=C	DUYJMQONPNNFPI-UHFFFAOYSA-N	2015	US-8946235-B2	Achiral Molecule	AZD-9291 AZD-9291 FREE BASE AZD9291 MERELETINIB OSIMERTINIB TAGRISSO	Y
Ponatinib	Iclusig	4	Ariad Pharmaceuticals	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'0LI'	3ik3 3oxz 3zos 4c8b 4qrc 4tyj 4u0i 4uxq 4v01 4v04 6eg9 6p3d 6tu9 7ote 7wf5	2	1	532.2	4.5	65.8	6	1	4	Ponatinib is indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy.	ABL1 BCR KIT RET TEK FLT3 FGFR1 FGFR2 FGFR3 FGFR4 LCK SRC LYN KDR PDGFRA	Atypical Tyr	Cc1ccc(cc1C#Cc2cnc3n2nccc3)C(=O)Nc4ccc(c(c4)C(F)(F)F)CN5CCN(CC5)C	PHXJVRSECIGDHY-UHFFFAOYSA-N	2012	US-8114874-B2	Achiral Molecule	AP-24534 AP24534 ICLUSIG PONATINIB	Y
Fedratinib	Inrebic	4	Sanofi	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'2TA'	4ogj 4ps5 6vne	nan	1	524.3	4.8	108.5	8	3	10	On august 2019, FDA approved fedratinib to treat adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis	JAK2 FLT3 BRD4	(*) Tyr	Cc1cnc(nc1Nc2cccc(c2)S(=O)(=O)NC(C)(C)C)Nc3ccc(cc3)OCCN4CCCC4	JOOXLOJCABQBSG-UHFFFAOYSA-N	2019	US-7528143-B2	Achiral Molecule	FEDRATINIB SAR-302503 SAR302503 TG-101348 TG101348	Y
Nintedanib	Ofev;Vargatef	4	Boehringer Ingelheim	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'XIN'	3c7q 5maf 5te0 6nec	1	1	539.3	3.6	94.2	7	2	7	Nintedanib is indicated for the treatment of idiopathic pulmonary fibrosis (IPF).	FLT1 KDR FLT4 FGFR1 FGFR2 FGFR3 FLT3 LCK LYN SRC	Tyr	CN1CCN(CC1)CC(=O)N(C)c2ccc(cc2)N/C(=C\3/c4ccc(cc4NC3=O)C(=O)OC)/c5ccccc5	XZXHXSATPCNXJR-ZIADKAODSA-N	2014	US-6762180-B1	Achiral Molecule	BIBF 1120 BIBF-1120 BIBF1120 INTEDANIB NINTEDANIB OFEV VARGATEF	Y
Trametinib	Mekinist	4	GlaxoSmithKline	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'QOM'	7jur 7jux 7m0y	3	1	615.1	3.9	107.1	8	2	5	Trametinib is indicated for the treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.	BRAF MAP2K1 MAP2K2	STE TKL	Cc1c2c(c(n(c1=O)C)Nc3ccc(cc3F)I)c(=O)n(c(=O)n2c4cccc(c4)NC(=O)C)C5CC5	LIRYPHYGHXZJBZ-UHFFFAOYSA-N	2013	None	Achiral Molecule	GSK-1120212 GSK1120212 JTP 74057 JTP-74057 MEKINIST TMT-212 TMT212 TRAMETINIB	Y	293-303
Filgotinib		4	Galapagos	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'2HB'	4p7e 5ut5	1	0	425.2	2.0	96.7	7	1	5	nan	JAK1	Tyr	c1cc(n2c(c1)nc(n2)NC(=O)C3CC3)c4ccc(cc4)CN5CCS(=O)(=O)CC5	RIJLVEAXPNLDTC-UHFFFAOYSA-N	nan	None	Single Stereoisomer	FILGOTINIB G-146034 G146034 GLPG-0634 GLPG0634 GS-6034 FREE BASE	N
Infigratinib		4	Novartis	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'07J'	3tt0	1	2	559.2	5.4	95.1	8	2	8	On May 2021, FDA approved infigratinib to treat adults with cholangiocarcinoma whose disease meets certain criteria	FGFR1 FGFR2 FGFR3	Tyr	CCN1CCN(CC1)c2ccc(cc2)Nc3cc(ncn3)N(C)C(=O)Nc4c(c(cc(c4Cl)OC)OC)Cl	QADPYRIHXKWUSV-UHFFFAOYSA-N	2021	US-8552002-B2	Achiral Molecule	BGJ-398 BGJ398 INFIGRATINIB MVP-BGJ398 NVP-BGJ398	Y
Fostamatinib	Tavalisse	4	Rigel Pharmaceuticals	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'2RC'	4o75	nan	2	580.1	3.1	186.7	12	4	10	Indicated for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who have had an insufficient response to a previous treatment	SYK	Tyr	CC1(C(=O)N(c2c(ccc(n2)Nc3c(cnc(n3)Nc4cc(c(c(c4)OC)OC)OC)F)O1)COP(=O)(O)O)C	GKDRMWXFWHEQQT-UHFFFAOYSA-N	2018	US-7449458-B2	Achiral Molecule	FOSTAMATINIB R-788 R-788 FREE ACID R-935788 R-935788 FREE ACID R788 FREE ACID R935788 FREE ACID	Y
Pacritinib		4	Cell Therapeutics	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'6T3'	5lbz	1	0	472.2	5.0	68.7	7	1	4	On February 2022, FDA approved pacritinib to treat intermediate or high-risk primary or secondary myelofibrosis in adults with low platelets	JAK2	Tyr	c1cc2cc(c1)-c3ccnc(n3)Nc4ccc(c(c4)COC/C=C/COC2)OCCN5CCCC5	HWXVIOGONBBTBY-ONEGZZNKSA-N	2022	None	Achiral Molecule	ONX-0803 PACRITINIB SB-1518 SB1518	Y
Abemaciclib	Verzenio;Verzenios	4	Eli Lilly	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'6ZV'	5l2s 7o7j 7o7k 7sj3	1	1	506.3	4.9	75.0	8	1	7	On September 28, 2017, the Food and Drug Administration approved abemaciclib (VERZENIO, Eli Lilly and Company) in combination with fulvestrant for women with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. In addition, abemaciclib was approved as monotherapy for women and men with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.	CDK4 CDK6	CMGC	CCN1CCN(CC1)Cc2ccc(nc2)Nc3ncc(c(n3)c4cc5c(c(c4)F)nc(n5C(C)C)C)F	UZWDCWONPYILKI-UHFFFAOYSA-N	2017	US-7855211-B2	Achiral Molecule	ABEMACICLIB LY-2835219 LY2835219 VERZENIO VERZENIOS	Y
Icotinib		4	Zhejiang Beta Pharma	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	0	391.2	3.2	74.7	7	1	2	Icotinib hydrochloride is a novel epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor, exhibits encouraging efficacy and tolerability in patients with advanced non-small-cell lung cancer (NSCLC) who failed previous chemotherapy.	EGFR	Tyr	C#Cc1cccc(c1)Nc2c3cc4c(cc3ncn2)OCCOCCOCCO4	QQLKULDARVNMAL-UHFFFAOYSA-N	2011	None	Achiral Molecule	BPI-2009 BPI-2009H ICOTINIB	N
Umbralisib		4	TG Therapeutics	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	2	571.2	6.7	109.1	8	1	6	On February 2021, FDA approved umbralisib for the treatment of certain patients with marginal zone lymphoma and follicular lymphoma	nan		C[C@@H](c1c(c(=O)c2cc(ccc2o1)F)c3cccc(c3)F)n4c5c(c(n4)c6ccc(c(c6)F)OC(C)C)c(ncn5)N	IUVCFHHAEHNCFT-INIZCTEOSA-N	2021	US-9150579-B2	Single Stereoisomer	RP-5264 RP5264 TGR 1202 TGR-1202 BASE TGR-1202 FREE BASE UMBRALISIB	Y	139-142
Upadacitinib	Rinvoq	4	Abbvie	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	0	380.2	2.9	78.3	4	2	3	On august 2019, FDA approved fedratinib to treat adults with moderately to severely active rheumatoid arthritis	JAK1	Tyr	CC[C@@H]1CN(C[C@@H]1c2cnc3n2c4cc[nH]c4nc3)C(=O)NCC(F)(F)F	WYQFJHHDOKWSHR-MNOVXSKESA-N	2019	US-8962629-B2	Single Stereoisomer	ABT-494 RINVOQ UPADACITINIB UPADACITINIB ANHYDROUS UPADACITINIB HEMIHYDRATE	Y	16-19
Lenvatinib	Kisplyx;Lenvima	4	Eisai	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'LEV'	3wzd 5zv2	1.5	0	426.1	4.1	115.6	5	3	6	Lenvatinib is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.	FLT1 KDR FLT4 FGFR1 FGFR2 FGFR3 FGFR4 KIT	Tyr	COc1cc2c(cc1C(=O)N)c(ccn2)Oc3ccc(c(c3)Cl)NC(=O)NC4CC4	WOSKHXYHFSIKNG-UHFFFAOYSA-N	2015	US-7253286-B2	Achiral Molecule	E-7080 ER-203492-00 KISPLYX LENVATINIB LENVIMA	Y
Vandetanib	Caprelsa;Zactima	4	Ipr Pharmaceuticals	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'ZD6'	2ivu	1.5	1	474.1	5.0	59.5	6	1	6	Vandetanib is currently approved as an alternative to local therapies for both unresectable and disseminated disease. Because Vandetanib can prolong the Q-T interval, it is contraindicated for use in patients with serious cardiac complications such as congenital long QT syndrome and uncompensated heart failure.	VEGFA EGFR PTK6 TEK RET	(*) Tyr	CN1CCC(CC1)COc2cc3c(cc2OC)c(ncn3)Nc4ccc(cc4F)Br	UHTHHESEBZOYNR-UHFFFAOYSA-N	2011	US-7173038-B1	Achiral Molecule	CAPRELSA GNF-PF-2188 NSC-744325 NSC-760766 VANDETANIB ZACTIMA ZD-64 ZD-6474 ZD6474	Y
Vemurafenib	Zelboraf	4	Hoffmann-La Roche	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'032'	3og7 4rzv 5hes	1.5	1	489.1	5.5	91.9	4	2	7	Vemurafenib is approved since 2011 for the treatment of metastatic melanoma with a mutation on BRAF in the valine located in the exon 15 at codon 600, this mutation is denominated as V600E.	BRAF	TKL	CCCS(=O)(=O)Nc1ccc(c(c1F)C(=O)c2c[nH]c3c2cc(cn3)c4ccc(cc4)Cl)F	GPXBXXGIAQBQNI-UHFFFAOYSA-N	2011	US-7504509-B2	Achiral Molecule	PLX-4032 PLX4032 RG 7204 RG-7204 RO 5185426 RO-51-85426 RO-5185426 VEMURAFENIB ZELBORAF	Y	272°C
Larotrectinib	Vitrakvi	4	Array BioPharma	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	0	428.2	2.9	86.0	6	2	3	On november 26, 2018, the FDA approved larotrectinib to treat patients whose cancers have a specific genetic feature (biomarker)	NTRK1 NTRK2 NTRK3	Tyr	c1cc(c(cc1F)[C@H]2CCCN2c3ccn4c(n3)c(cn4)NC(=O)N5CC[C@@H](C5)O)F	NYNZQNWKBKUAII-KBXCAEBGSA-N	2018	US-8513263-B2	Single Stereoisomer	ARRY-470 BAY-2757556 BAY2757556 LAROTRECTINIB LOXO-101	Y
Lapatinib	Tykerb;Tyverb	4	GlaxoSmithKline	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'FMM'	1xkk 3bbt	1.5	2	580.1	6.1	106.4	8	2	11	Indicated in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress the human epidermal receptor type 2 (HER2) protein and who have received prior therapy including an anthracycline, a taxane, and trastuzuma.	EGFR ERBB2	Tyr	CS(=O)(=O)CCNCc1ccc(o1)c2ccc3c(c2)c(ncn3)Nc4ccc(c(c4)Cl)OCc5cccc(c5)F	BCFGMOOMADDAQU-UHFFFAOYSA-N	2007	US-7157466-B2	Achiral Molecule	GSK-572016 GW-2016 GW-572016 GW-572016X GW572016 LAPATINIB TYVERB	Y
Zanubrutinib	Brukinsa	4	BeiGene	ChemSpider ChEMBL PubChem BindingDB			nan	0	471.2	4.2	102.5	6	2	6	Zanubrutinib (BGB-3111) is a potent, selective and and irreversible BTK inhibitor that is being investigated for clinical utility in the treatment of hematological cancers, such as non-Hodgkin's lymphoma and chronic lymphocytic leukemia (CLL) [1-2].	nan		C=CC(=O)N1CCC(CC1)C2CCNc3n2nc(c3C(=O)N)c4ccc(cc4)Oc5ccccc5	RNOAOAWBMHREKO-UHFFFAOYSA-N	2019	US-9447106-B2	Single Stereoisomer		Y
Nilotinib	Tasigna	4	Novartis	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'NIL'	3cs9 3gp0 5mo4	2	2	529.2	6.4	97.6	7	2	6	For the potential treatment of various leukemias, including chronic myeloid leukemia (CML).	ABL1 KIT	Tyr	Cc1ccc(cc1Nc2nccc(n2)c3cccnc3)C(=O)Nc4cc(cc(c4)n5cc(nc5)C)C(F)(F)F	HHZIURLSWUIHRB-UHFFFAOYSA-N	2007	US-7169791-B2	Achiral Molecule	AMN 107 AMN-107 AMN107 NILOTINIB NSC-747599 TASIGNA	Y
Imatinib	Gleevec	4	Novartis	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'STI'	1iep 1opj 1t46 1xbb 2hyy 2oiq 2pl0 3fw1 3gvu 3hec 3k5v 3ms9 3mss 3oez 3pyy 4bkj 4csv 4r7i 5mqt 6hd4 6hd6 6jol 6ktn 6npe 6npu 6npv 6vxh 7n9g	2	0	493.3	4.6	86.3	7	2	7	For the treatment of Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML), Ph+ acute lymphoblastic leukaemia, myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome and/or chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans, and malignant gastrointestinal stromal tumors (GIST).	KIT RET NTRK1 CSF1R PDGFRA DDR1 ABL1 PDGFRB	Tyr	Cc1ccc(cc1Nc2nccc(n2)c3cccnc3)NC(=O)c4ccc(cc4)CN5CCN(CC5)C	KTUFNOKKBVMGRW-UHFFFAOYSA-N	2001	US-6958335-B2	Achiral Molecule	GLAMOX GLEEVEC IMATINIB NSC-743414 NSC-759854 STI-571	Y	226°C (mesylate salt)
Idelalisib	Zydelig	4	Gilead Sciences	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'40L'	4xe0	1	0	415.2	3.8	101.4	7	2	5	Idelalisib is indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies.	PIK3CD	Atypical	CC[C@@H](c1nc2cccc(c2c(=O)n1c3ccccc3)F)Nc4c5c([nH]cn5)ncn4	IFSDAJWBUCMOAH-HNNXBMFYSA-N	2014	US-6800620-B2	Single Stereoisomer	CAL-101 GS-1101 GS-11CAL-101 IDELALISIB ZYDELIG	Y
Gilteritinib	Xospata	4	Astellas Pharma	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'C6F'	6jqr 7ab1	nan	1	552.4	2.7	121.1	10	3	9	On november 28, 2018, the FDA approved gilteritinib to treat patients who have relapsed or refractory acute myeloid leukemia (AML)	FLT3 AXL ALK	Tyr	CCc1c(nc(c(n1)C(=O)N)Nc2ccc(c(c2)OC)N3CCC(CC3)N4CCN(CC4)C)NC5CCOCC5	GYQYAJJFPNQOOW-UHFFFAOYSA-N	2018	US-8969336-B2	Achiral Molecule	ASP-2215 ASP2215 GILTERITINIB	Y
Dasatinib	Dasatinib;Sprycel	4	Bristol Myers Squibb	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'1N1'	2gqg 2y6o 2zva 3g5d 3k54 3lfa 3oct 3oht 3qlg 3sxr 4qms 4xey 4xli 5bvw 5h2u 5i9y 5owr 5vcv 6bsd 6fnm 7erk 7n9g	1	0	487.2	3.3	106.5	9	3	7	For the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy. Also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy.	ABL1 SRC EPHA2 LCK YES1 KIT PDGFRB ABL2 FYN	Tyr	Cc1cccc(c1NC(=O)c2cnc(s2)Nc3cc(nc(n3)C)N4CCN(CC4)CCO)Cl	ZBNZXTGUTAYRHI-UHFFFAOYSA-N	2006	US-7491725-B2	Achiral Molecule	BMS-354825 BMS-354825 HYDRATE BMS-354825-03 DASATINIB DASATINIB ANHYDROUS DASATINIB HYDRATE DASATINIB MONOHYDRATE NSC-759877 SPRYCEL	Y	280-286 °C
Gefitinib	Iressa	4	Astrazeneca	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'IRE'	2ito 2ity 2itz 3ug2 4i22 4wkq 5y7z 5y80	1.5	0	446.2	4.3	68.7	7	1	8	For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.	EGFR	Tyr	COc1cc2c(cc1OCCCN3CCOCC3)c(ncn2)Nc4ccc(c(c4)Cl)F	XGALLCVXEZPNRQ-UHFFFAOYSA-N	2003	None	Achiral Molecule	GEFITINIB IRESSA NSC-759856 ZD-1839 ZD1839	Y
Flumatinib		4	Jiangsu Hengrui Medicine	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	2	562.2	5.0	99.2	8	2	7	nan	BCR ABL1 PDGFRB KIT	Atypical Tyr	Cc1c(cc(cn1)NC(=O)c2ccc(c(c2)C(F)(F)F)CN3CCN(CC3)C)Nc4nccc(n4)c5cccnc5	BJCJYEYYYGBROF-UHFFFAOYSA-N	nan	NaN	NaN	FLUMATINIB FLUMBATINIB HH-GV678 HHGV-678	N
Regorafenib	Stivarga	4	Bayer	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			2	1	482.1	5.7	92.3	4	3	5	Regorafenib is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy. Regorafenib is also indicated for the treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	FLT1 KDR FLT4 KIT PDGFRA PDGFRB FGFR1 FGFR2 TEK DDR2 NTRK1 EPHA2 RAF1 BRAF MAPK11 FRK ABL1 RET	Tyr TKL CMGC	CNC(=O)c1cc(ccn1)Oc2ccc(c(c2)F)NC(=O)Nc3ccc(c(c3)C(F)(F)F)Cl	FNHKPVJBJVTLMP-UHFFFAOYSA-N	2012	US-7351834-B1	Achiral Molecule	BAY 73-4506 BAY 73-4506 MONOHYDRATE BAY-73-4506 BAY-734506 REGORAFENIB STIVARGA	Y
Sorafenib	Nexavar	4	Bayer	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'BAX'	1uwh 1uwj 3gcs 3heg 3rgf 3wze 4asd 5hi2	2	1	464.1	5.5	92.3	4	3	5	Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.	BRAF RAF1 FLT4 KDR FLT3 PDGFRB KIT FGFR1 RET FLT1	Tyr TKL	CNC(=O)c1cc(ccn1)Oc2ccc(cc2)NC(=O)Nc3ccc(c(c3)C(F)(F)F)Cl	MLDQJTXFUGDVEO-UHFFFAOYSA-N	2005	US-8618141-B2	Achiral Molecule	BAY 43-9006 BAY-43-9006 NEXAVAR SORAFENIB	Y	205.6 °C
Ribociclib	Kisqali	4	Novartis	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'6ZZ'	5l2t	1	0	434.3	2.8	91.2	8	2	5	Kisqali (ribociclib) is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably.	CDK4 CDK6	CMGC	CN(C)C(=O)c1cc2cnc(nc2n1C3CCCC3)Nc4ccc(cn4)N5CCNCC5	RHXHGRAEPCAFML-UHFFFAOYSA-N	2017	US-8324225-B2	Achiral Molecule	LEE-011 LEE-011A LEE011 LEE011A NVP-LEE011 RIBOCICLIB	Y
Axitinib	Inlyta	4	Pfizer	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'AXI'	4ag8 4agc 4twp 4wa9	2	0	386.1	4.6	70.7	4	2	5	Used in kidney cell cancer and investigated for use/treatment in pancreatic and thyroid cancer.	FLT1 KDR FLT4	Tyr	CNC(=O)c1ccccc1Sc2ccc3c(c2)[nH]nc3/C=C/c4ccccn4	RITAVMQDGBJQJZ-FMIVXFBMSA-N	2012	US-6534524-B1	Achiral Molecule	AG-013736 AG-13736 AXITINIB INLYTA NSC-757441	Y
Cobimetinib	Cotellic	4	Hoffmann-La Roche	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'EUI'	4an2 4lmn 7juy 7m0v	3	1	531.1	3.8	64.6	4	3	4	For the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. Cobimetinib is used in combination with vemurafenib, a BRAF inhibitor.	MAP2K1	STE	c1c(cc(c(c1)Nc2c(c(ccc2C(=O)N3C[C@@](C3)(O)[C@H]4NCCCC4)F)F)F)I	BSMCAPRUBJMWDF-KRWDZBQOSA-N	2015	US-7803839-B2	Single Stereoisomer	COBIMETINIB COTELLIC GDC 0623 GDC 0973 GDC-0623 GDC-0973 RG 7420 RG-7420 RG-7421 RG7420 XL 518 XL-518 XL518	Y
Avapritinib	Ayvakit	4	Blueprint Medicines	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology FDA SRS BindingDB			nan	0	498.2	2.6	106.3	10	1	5	On January 2020 FDA approved avapritinib to treat adults with unresectable or metastatic gastrointestinal stromal tumor (GIST)	nan		C[C@](c1ccc(cc1)F)(c2cnc(nc2)N3CCN(CC3)c4c5cc(cn5ncn4)c6cnn(c6)C)N	DWYRIWUZIJHQKQ-SANMLTNESA-N	2020	US-9200002-B2	Single Stereoisomer	70C366 AVAPRITINIB AYVAKIT BLU-285 C-366 X-720776 X720776	Y
Alectinib	Alecensa	4	Hoffmann-La Roche	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'EMH'	3aox 5xv7	1	0	482.3	4.8	72.4	5	1	3	Alectinib is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.	ALK	Tyr	CCc1cc2c(cc1N3CCC(CC3)N4CCOCC4)C(c5c(c6ccc(cc6[nH]5)C#N)C2=O)(C)C	KDGFLJKFZUIJMX-UHFFFAOYSA-N	2015	US-9126931-B2	Achiral Molecule	AF-802 AF802 ALECENSA ALECTINIB CH-5424802 CH5424802 RO-5424802 RO5424802	Y
Asciminib		4	Novartis	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'AY7'	5mo4	nan	0	449.1	3.5	103.4	6	3	6	On October 2021, FDA approved asciminib To treat Philadelphia chromosome-positive chronic myeloid leukemia with disease that meets certain criteria	nan		c1cc(ccc1NC(=O)c2cc(c(nc2)N3CC[C@H](C3)O)c4ccn[nH]4)OC(F)(F)Cl	VOVZXURTCKPRDQ-CQSZACIVSA-N	2021	None	Single Stereoisomer	ABL-001 ABL001 ABL001-NX ASCIMINIB NVP-ABL001	Y
Apatinib		4	Bukwang Pharmaceutical	ChemSpider PubChem Guide to Pharmacology ZINC			nan	1	397.2	5.1	90.7	5	2	5	Apatinib mesylate is an orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. The free-base form is also known as Rivoceranib. Apatinib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases.	KDR	Tyr	N#CC1(CCCC1)c1ccc(cc1)NC(=O)c1cccnc1Nc1cnccc1C	MGZNERAVOCFMCU-UHFFFAOYSA-N	2014	NaN	NaN	VP-16 APATINIBMESYLATE YN968D1,(AITAN® CAPECITABINE NO. NAVELBINE+AITAN SPA PEMETREXED PLATINU OXALIPLATIN APATINIB 500MG AITAN ALBUMIN PACLITAXEL YEW S-1 ESYLATE APATINIB APATINIB GROUP AI TAN REATMENT GROUP YN968D1 RIVOCERANIB APATINIB APATINIB 750MG ARGET THERAPY STUDY DRUG H20140103 APATINIB TABLETS SHR-1210 CARBOPLATIN XELOX EGAFUR IE CHEMOTHERAPY SURGERY ATAN IRINOTECAN ARM A PACLITAXOL CRYOABLATION 5-FLUOROURACIL APATINIB MESYLATE DOCETAXEL EMOZOLOMIDE（TMZ） EMOZOLOMIDE APATINIB MESYLAS S1	N
Anlotinib		4	Advenchen Laboratories	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS			nan	0	407.2	4.8	82.4	5	2	6	Anlotinib (AL3818) is a non-selective inhibitor of multiple receptor tyrosine kinases, including vascular endothelial growth factor receptor type 2 (VEGFR-2, FLT1) and type 3 (VEGFR-3, FLT4). It is being investigated for antineoplastic and anti-angiogenic potential. The dihydrochloride has PubChem CID: 57380530. Preparation and crystallisation of AL3818 is described in patent WO2016179123.	KDR FLT4	Tyr	Cc1cc2c([nH]1)ccc(c2F)Oc3ccnc4c3cc(c(c4)OCC5(CC5)N)OC	KSMZEXLVHXZPEF-UHFFFAOYSA-N	nan	NaN	NaN	AL 3818 AL-3818 AL3818 ANLOTINIB CATEQUENTINIB	N
Belumosudil		4	Surface logix	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'ICQ'	7z39	nan	0	452.2	4.8	104.8	6	3	7	On July 2021, FDA approved belumosudil to treat chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy	nan		CC(C)NC(=O)COC1=CC=CC(=C1)C2=NC3=CC=CC=C3C(=N2)NC4=CC5=C(C=C4)NN=C5	GKHIVNAUVKXIIY-UHFFFAOYSA-N	2021	None	Achiral Molecule	BELUMOSUDIL KD-025 KD025 ROCK2 INHIBITOR KD025 SLX-2119 SLX-2119 FREE BASE	Y
Alpelisib	Piqray	4	Novartis	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'1LT'	4jps 7myo 7pg6 8gua 8gub 8gud	nan	0	441.1	3.8	101.2	5	2	4	On may 2019, FDA approved alpelisib to treat breast cancer	PIK3CA	Atypical	Cc1c(sc(n1)NC(=O)N2CCC[C@H]2C(=O)N)c3ccnc(c3)C(C)(C)C(F)(F)F	STUWGJZDJHPWGZ-LBPRGKRZSA-N	2019	US-8227462-B2	Single Stereoisomer	ALPELISIB BYL-719 BYL719 NVP-BYL719 PIQRAY	Y
Brigatinib	Alunbrig	4	Ariad Pharmaceuticals	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe ZINC FDA SRS BindingDB	'6GY'	6mx8 7aem	1	2	583.3	5.1	85.9	9	2	8	The anaplastic lymphoma kinase positive, metastatic non-small cell lung cancer (ALK+ NSCLC), represents only 3-5% of the NSCLC cancer cases, but the ALK mutation, overexpression and presence in several oncogenic fusion proteins in solid and hematologic tumors have pointed out the importance as well as its potential as a cancer therapy target. The ALK-related cases of NSCLC are associated with the presence of the fusion gene EML4-ALK which fused the ALK protein with the echinoderm microtubule-associated protein like-4 whose original function is the correct formation of microtubules. The presence of the aberrant fusion protein results in abnormal signaling that provokes increased cell growth, proliferation and survival. Crizotinib is indicated for the treatment of such cases but the presence of ALK kinase domain mutations confer resistance to the treatment. Thus, brigatinib is indicated for the treatment of patients with ALK+ NSCLC with intolerance to Crizotinib.	ALK EGFR	Tyr	CN1CCN(CC1)C2CCN(CC2)c3ccc(c(c3)OC)Nc4ncc(c(n4)Nc5ccccc5P(=O)(C)C)Cl	AILRADAXUVEEIR-UHFFFAOYSA-N	2017	US-9012462-B2	Achiral Molecule	ALUNBRIG AP-26113 AP26113 BRIGATINIB	Y
Copanlisib	Aliqopa	4	Bayer	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'6E2'	5g2n	1	1	480.2	0.7	139.8	11	2	7	Indicated for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies.	PIK3CA PIK3CB	Atypical	COc1c(ccc2c1N=C(N3C2=NCC3)NC(=O)c4cnc(nc4)N)OCCCN5CCOCC5	PZBCKZWLPGJMAO-UHFFFAOYSA-N	2017	US-7511041-B2	Achiral Molecule	BAY 80-6946 BAY-80-6946 BAY80-6946 COPANLISIB	Y
Dabrafenib	Tafinlar	4	GlaxoSmithKline	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'P06'	4xv2 5csw 5hie 6hj2 6v2u 7riv	1.5	2	519.1	5.4	110.9	7	2	5	Dabrafenib is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.	BRAF RAF1 SIK1 NEK11 LIMK1	CAMK NEK TKL	CC(C)(C)c1nc(c(s1)c2ccnc(n2)N)c3cccc(c3F)NS(=O)(=O)c4c(cccc4F)F	BFSMGDJOXZAERB-UHFFFAOYSA-N	2013	US-7994185-B2	Achiral Molecule	DABRAFENIB GSK-2118436 GSK-2118436A GSK2118436 GSK2118436A TAFINLAR	Y
Crizotinib	Xalkori	4	Pfizer	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'VGH'	2wgj 2xp2 2yfx 3zbf 4anq 4ans 4c9w 5aaa 5aab 5aac 6imz	1	1	449.1	5.0	78.0	6	2	5	Crizotinib is used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic-lymphoma kinase (ALK)-positive as detected by a FDA-approved test.	ALK MET	Tyr	C[C@H](c1c(ccc(c1Cl)F)Cl)Oc2cc(cnc2N)c3cnn(c3)C4CCNCC4	KTEIFNKAUNYNJU-GFCCVEGCSA-N	2011	US-7230098-B2	Single Stereoisomer	CRIZOTINIB NSC-756645 PF-02341066 PF-2341066 XALKORI	Y
Abrocitinib		4	Pfizer	ChemSpider PubChem			nan	0	323.1	1.3	91.0	5	2	6	On January 2022, FDA approved abrocitinib to treat refractory, moderate-to-severe atopic dermatitis	nan		CCCS(=O)(=O)NC1CC(C1)N(C)c2c3cc[nH]c3ncn2	IUEWXNHSKRWHDY-UHFFFAOYSA-N	2022	None	Single Stereoisomer	CIBINQO PF-04965842 ABROCITINIB	Y
Dacomitinib	Vizimpro	4	Pfizer	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'1C9'	4i23 4i24	1	1	469.2	5.2	79.4	6	2	7	On october 27, 2018, the FDA approved dacomitinib to treat metastatic non-small-cell lung cancer	EGFR	Tyr	COc1cc2c(cc1NC(=O)/C=C/CN3CCCCC3)c(ncn2)Nc4ccc(c(c4)Cl)F	LVXJQMNHJWSHET-AATRIKPKSA-N	2018	US-7772243-B2	Achiral Molecule	DACOMITINIB PF-00299804	Y	184-187 ºC
Acalabrutinib	Calquence	4	Astrazeneca	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	0	465.2	3.3	118.5	7	2	4	Acalabrutinib is currently indicated for the treatment of adult patients with Mantle Cell Lymphoma (MCL) who have received at least one prior therapy	BTK	Tyr	CC#CC(=O)N1CCC[C@H]1c2nc(c3n2ccnc3N)c4ccc(cc4)C(=O)Nc5ccccn5	WDENQIQQYWYTPO-IBGZPJMESA-N	2017	US-7459554-B2	Single Stereoisomer	ACALABRUTINIB ACP-196 CALQUENCE	Y
Ceritinib	Zykadia	4	Novartis	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'4MK'	4mkc	1	2	557.2	6.4	105.2	8	3	9	Ceritinib is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.	ALK	Tyr	Cc1cc(c(cc1C2CCNCC2)OC(C)C)Nc3ncc(c(n3)Nc4ccccc4S(=O)(=O)C(C)C)Cl	VERWOWGGCGHDQE-UHFFFAOYSA-N	2014	US-7153964-B2	Achiral Molecule	CERITINIB CERITINIB[MI] LDK-378 LDK378 NVP-LDK-378-NX NVP-LDK378-NX ZYKADIA	Y
Binimetinib	Mektovi	4	Novartis	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS	'QO7'	7m0u	nan	0	440.0	3.0	88.4	6	3	6	On June 27, 2018, the Food and Drug Administration approved encorafenib and binimetinib in combination patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.	MAP2K1	STE	Cn1cnc2c1cc(c(c2F)Nc3ccc(cc3F)Br)C(=O)NOCCO	ACWZRVQXLIRSDF-UHFFFAOYSA-N	2018	US-7777050-B2	Achiral Molecule	ARRY 438162 ARRY-162 ARRY-438162 BINIMETINIB MEK-162 MEK162 MEKTOVI NVP-MEK162	Y
Bosutinib	Bosulif	4	Wyeth	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'DB8'	3soa 3ue4 4mxo 4mxx 4mxy 4mxz 4qmn 5ajq 5i9x 5vc3 5vcy 6fdy 6op9	1	2	529.2	5.2	82.9	8	1	9	Treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy in adult patients.	BCR ABL1 LYN HCK SRC CDK2 MAP2K1 MAP2K2 MAP3K2 CAMK2G	STE CAMK CMGC Atypical Tyr	CN1CCN(CC1)CCCOc2cc3c(cc2OC)c(c(cn3)C#N)Nc4cc(c(cc4Cl)Cl)OC	UBPYILGKFZZVDX-UHFFFAOYSA-N	2012	US-7417148-B2	Achiral Molecule	BOSULIF BOSUTINIB BOSUTINIB (AS MONOHYDRATE) BOSUTINIB HYDRATE BOSUTINIB MONOHYDRATE SK-606 SKI-606	Y
Afatinib	Gilotrif;Giotrif	4	Boehringer Ingelheim	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'0WM'	4g5j	1	0	485.2	4.4	88.6	7	2	8	Afatinib is a kinase inhibitor indicated for the first-line treatment of patient with metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.	EGFR ERBB2 ERBB4	Tyr	CN(C)C/C=C/C(=O)Nc1cc2c(cc1O[C@H]3CCOC3)ncnc2Nc4ccc(c(c4)Cl)F	ULXXDDBFHOBEHA-CWDCEQMOSA-N	2013	US-RE43431-E1	Single Stereoisomer	AFATINIB BIBW 2992 BIBW-2992 BIBW2992 GILOTRIF GIOTRIF NSC-750691 TOMTOVOK TOVOK	Y
Ripretinib	Qinlock	4	Deciphera Pharmaceuticals	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology FDA SRS			nan	2	509.1	5.7	88.0	5	3	5	Ripretinib (DCC-2618) is an orally bioavailable, potent pan-KIT and PDGFRα kinase inhibitor being developed by Dicephera Pharmaceuticals. It is in clinical development for the treatment of malignancies that are driven by KIT and/or PDGFRα, for example gastrointestinal stromal tumors, glioblastoma multiforme and systemic mastocytosis. Ripretinib has activity across a broad range of resistance mutations in its target kinases, that emerge in response to imatinib treatment. Ripretinib binds to the 'switch pocket' of KIT, a domain that regulates the enzyme's catalytic conformation. Compounds that act in this way are often referred to as switch control inhibitors.	nan		CCn1c2cc(ncc2cc(c1=O)c3cc(c(cc3Br)F)NC(=O)Nc4ccccc4)NC	CEFJVGZHQAGLHS-UHFFFAOYSA-N	2020	US-8188113-B2	Achiral Molecule	DCC-2618 QINLOCK RIPRETINIB	Y
Neratinib	Nerlynx	4	Puma Biotechnology	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	2	556.2	5.9	112.4	8	2	11	For use as an extended adjuvant treatment in adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy	ERBB2 EGFR	Tyr	CCOc1cc2c(cc1NC(=O)/C=C/CN(C)C)c(c(cn2)C#N)Nc3ccc(c(c3)Cl)OCc4ccccn4	JWNPDZNEKVCWMY-VQHVLOKHSA-N	2017	US-7399865-B2	Achiral Molecule	CDP-820 HKI-272 NERATINIB WAY-179272	Y
Ruxolitinib	Jakafi;Jakavi	4	Incyte Corporation	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'RXT'	4u5j 6vgl 6vnk 6wtn 7f3g	1	0	306.2	3.5	83.2	5	1	4	Treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera (post-PV) myelofibrosis and post-essential thrombocythemia (post-ET) myelofibrosis. [Lexicomp] Myeolofibrosis is the proliferation of abnormal bone marrow stem cells which cause fibrosis (the excessive formation of connective tissue).	JAK1 JAK2	Tyr	c1c[nH]c2c1c(ncn2)c3cnn(c3)[C@H](CC#N)C4CCCC4	HFNKQEVNSGCOJV-OAHLLOKOSA-N	2011	US-7598257-B2	Single Stereoisomer	INC-424 INC424 INCB-018424 INCB-18424 INCB018424 JAKAVI RUXOLITINIB	Y	86
Selpercatinib	Retevmo	4	Loxo Oncology	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology FDA SRS BindingDB			nan	1	525.2	3.3	112.0	10	1	8	On May 2020 FDA approved selpercatinib to treat lung and thyroid cancers.	nan		COC1C=CC(CN2C3CN(CC2C3)C2C=CC(=CN=2)C2=CC(=CN3N=CC(C#N)=C32)OCC(C)(C)O)=CN=1	XIIOFHFUYBLOLW-UHFFFAOYSA-N	2020	US-10112942-B2	Achiral Molecule	LOXO-292 LY-3527723 LY3527723 RET INHIBITOR LOXO-292 RETEVMO SELPERCATINIB	Y
Selumetinib		4	Astrazeneca	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'3EW'	4u7z 7jut 7juz 7m0t	3	0	456.0	3.5	88.4	6	3	6	On April 2020 FDA approved selumetinib to treat neurofibromatosis type 1, a genetic disorder of the nervous system causing tumors to grow on nerves.	MAP2K1 MAP2K2	STE	Cn1cnc2c1cc(c(c2F)Nc3ccc(cc3Cl)Br)C(=O)NOCCO	CYOHGALHFOKKQC-UHFFFAOYSA-N	2020	US-7425637-B2	Achiral Molecule	ARRY-142886 ARRY-886 AZD-6244 AZD6244 SELUMETINIB	Y
Sunitinib	Sutent	4	Cp Pharmaceuticals	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'B49'	2y7j 3g0e 3g0f 3miy 3ti1 4agd 4ks8 4qmz 6jok 6m11 6nfy 6nfz 6ng0 6v0x	1	0	398.2	3.3	77.2	3	3	7	For the treatment of advanced renal cell carcinoma as well as the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate.	PDGFRB FLT1 KIT KDR FLT4 FLT3 CSF1R PDGFRA	Tyr	CCN(CC)CCNC(=O)c1c(c([nH]c1C)/C=C\2/c3cc(ccc3NC2=O)F)C	WINHZLLDWRZWRT-ATVHPVEESA-N	2006	US-6573293-B2	Achiral Molecule	NSC-736511 NSC-750690 SU-011248 SU-11248 SU011248 SUNITINIB SUTENT	Y
Midostaurin	Rydapt	4	Novartis Pharmaceuticals Corp	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'2K2'	4nct	nan	2	570.2	5.9	77.7	6	1	3	On april 28 , 2017, the FDA approved midostaurin to treat acute myeloid leukemia	nan		C[C@@]12[C@@H]([C@@H](C[C@@H](O1)n3c4ccccc4c5c3c6n2c7ccccc7c6c8c5C(=O)NC8)N(C)C(=O)c9ccccc9)OC	BMGQWWVMWDBQGC-IIFHNQTCSA-N	2017	US-7973031-B2	Single Stereoisomer	CGP 41251 CGP-41251 MIDOSTAURIN NSC-656576 NVP-PKC412 PKC 412 PKC-412 RYDAPT	Y	235-260
Tepotinib		4	Merck	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'3E8'	4r1v	1	0	492.2	4.0	96.9	8	0	7	On February 2021, FDA approved tepotinib to treat non-small cell lung cancer	MET	Tyr	CN1CCC(CC1)COc2cnc(nc2)c3cccc(c3)Cn4c(=O)ccc(n4)c5cccc(c5)C#N	AHYMHWXQRWRBKT-UHFFFAOYSA-N	2021	US-8329692-B2	Achiral Molecule	EMD 1214063 EMD-1214063 EMD1214063 MSC-2156119 MSC-2156119J MSC2156119 TEPOTINIB	Y
Lorlatinib	Lorbrena	4	Pfizer	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'5P8'	4cli 4clj 4uxl 5a9u 5aa8 5aa9	1	0	406.2	2.8	110.1	7	1	0	On november 2, 2018, the FDA approved lorlatinib to treat patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer	ALK ROS1	Tyr	C[C@@H]1c2cc(ccc2C(=O)N(Cc3c(c(n(n3)C)C#N)-c4cc(c(nc4)N)O1)C)F	IIXWYSCJSQVBQM-LLVKDONJSA-N	2018	US-8680111-B2	Single Stereoisomer	LORBRENA LORLATINIB PF-06463922	Y
Tivozanib	Fotivda	4	Aveo Pharmaceuticals	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'AV9'	4ase 8bem	2	1	454.1	5.6	107.7	7	2	6	On March 2021, FDA approved tivozanib to treat patients with renal cell carcinoma	FLT1 KDR FLT4	Tyr	Cc1cc(no1)NC(=O)Nc2ccc(cc2Cl)Oc3ccnc4c3cc(c(c4)OC)OC	SPMVMDHWKHCIDT-UHFFFAOYSA-N	2021	US-6821987-B2	Achiral Molecule	ASP-4130 AV-951 FOTIVDA KIL-8951 KIL8951 KRN-951 TIVOZANIB	Y	220-233
Tofacitinib	Xeljanz	4	Pfizer	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'MI1'	3eyg 3fup 3lxk 3lxn 4oti	1	0	312.2	1.5	88.9	5	1	3	For the treatment of moderate to severe rheumatoid arthritis which is resistant or intolerant to methotrexate therapy. It may also be used as an adjunct to methotrexate therapy, or other non-biologic disease-modifying antirheumatic drugs (DMARDS), when methotrexate alone is not sufficient. Tofacitinib has also been investigated as a preventative therapy for kidney transplant rejections, and as a treatment for psoriasis, ulcerative colitis, and ankylosing spondylitis. It is not to be initiated in patients with a history of chronic or recurrent infections, or in the presence of active infection, even if localized, due to reports of serious and sometimes fatal infections (commonly pneumonia, herpes zoster and urinary tract infections). Use of tofacitinib is also discouraged in those who have been, or are likely to be, exposed to TB. An increased likelihood of exposure may be encountered by traveling to certain areas. In addition, tofacitinib is not to be used in patients with severe hepatic impairment, or low hemoglobin (less than 9g/dL). Cautioned is advised when using tofacitinib in patients at risk of gastrointestinal perforation, and in the elderly who are more susceptible to infection.	JAK1 JAK2 JAK3 TYK2	Tyr	C[C@@H]1CCN(C[C@@H]1N(C)c2c3cc[nH]c3ncn2)C(=O)CC#N	UJLAWZDWDVHWOW-YPMHNXCESA-N	2012	US-6965027-B2	Single Stereoisomer	550 CP 690550 CP- 690 550 CP-690 CP-690 FREE BASE CP-690,550 CP-690,550 FREE BASE CP-690-550 CP-690550 CP-690550 FREE BASE CP690,550 CP690550 TASOCITINIB TOFACITINIB	Y	White crystalline solid. MP: 199-206 °C /Tofacitinib monocitrate/
Duvelisib	Copiktra	4	Infinity Pharmacueticals	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	0	416.1	4.5	88.5	6	2	4	On october 27, 2018, the FDA approved duvelisib to treat relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma and follicular lymphoma	PIK3CD PIK3CG	Atypical	C[C@@H](c1cc2cccc(c2c(=O)n1c3ccccc3)Cl)Nc4c5c([nH]cn5)ncn4	SJVQHLPISAIATJ-ZDUSSCGKSA-N	2018	US-8193182-B2	Single Stereoisomer	COPIKTRA DUVELISIB DUVELISIB HYDRATE DUVELISIB MONOHYDRATE INK-1147 INK-1197 IPI-145	Y	>190 ºC
Ibrutinib	Imbruvica	4	Pharmacyclics	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'1E8'	4ifg 4rz7 5p9i 5yu9 6l8l 6yg2 6yz4	1.5	0	440.2	4.2	99.2	7	1	5	Ibrutinib was approved by the FDA for the treatment of mantle cell lymphoma, and later in February 2014 for the treatment of chronic lymphocytic leukemia	BTK	Tyr	C=CC(=O)N1CCC[C@H](C1)n2c3c(c(n2)c4ccc(cc4)Oc5ccccc5)c(ncn3)N	XYFPWWZEPKGCCK-GOSISDBHSA-N	2013	US-7514444-B2	Single Stereoisomer	CRA-032765 IBRUTINIB IMBRUVICA PC-32765 PCI 32765 PCI-32765 PCI-32765-00	Y	149-158ºC
Pazopanib	Votrient	4	GlaxoSmithKline	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			1	0	437.2	3.1	119.0	8	2	5	Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)	FLT1 KDR FLT4 PDGFRA PDGFRB KIT FGFR3 ITK FGFR1	Tyr	Cc1ccc(cc1S(=O)(=O)N)Nc2nccc(n2)N(C)c3ccc4c(n(nc4c3)C)C	CUIHSIWYWATEQL-UHFFFAOYSA-N	2009	US-7105530-B2	Achiral Molecule	GW786034 NSC-752782 PAZOPANIB VOTRIENT	Y
Deucravacitinib		4	Bristol Myers Squibb	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology FDA SRS BindingDB			nan	0	425.2	1.2	139.2	8	3	7	On September 2022, FDA approved deucravacitinib to treat moderate-to-severe plaque psoriasis	TYK2	Tyr	C[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC	BZZKEPGENYLQSC-FIBGUPNXSA-N	2022	None	Achiral Molecule	BMS-986165 DEUCRAVACITINIB	Y
Capmatinib		4	Novartis	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			nan	0	412.1	3.4	85.1	6	1	4	On may 2020 FDA approved capmatinib to treat patients with non small cell lung cancer	MET	Tyr	CNC(=O)c1ccc(cc1F)c2cnc3ncc(n3n2)Cc4ccc5c(c4)cccn5	LIOLIMKSCNQPLV-UHFFFAOYSA-N	2020	US-7767675-B2	Achiral Molecule	CAPMATINIB INC-280 INC280 INCB-28060 INCB-28060 FREE BASE NVP-INC280 NVP-INC280-NX NYP-INC280-NX	Y
Cabozantinib	Cabometyx;Cometriq	4	Exelixis	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS BindingDB			2	2	501.2	5.5	98.8	6	2	8	For the treatment of metastatic medullary thyroid cancer and for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.	MET KDR RET	Tyr	COc1cc2c(ccnc2cc1OC)Oc3ccc(cc3)NC(=O)C4(CC4)C(=O)Nc5ccc(cc5)F	ONIQOQHATWINJY-UHFFFAOYSA-N	2012	US-7579473-B2	Achiral Molecule	BMS-907351 BMS-907351 FREE BASE CABOMETYX CABOZANTINIB COMETRIQ XL-184 XL-184 FREE BASE XL184	Y
Netarsudil	Rhopressa	4	Aerie Pharmaceutical	ChemSpider ChEMBL PubChem DrugBank Guide to Pharmacology ZINC FDA SRS			nan	0	453.2	4.9	94.3	5	2	7	On december 18, 2017, the FDA approved netarsudil to treat glaucoma or ocular hypertension	nan		Cc1ccc(c(c1)C)C(=O)OCc2ccc(cc2)[C@@H](CN)C(=O)Nc3ccc4cnccc4c3	OURRXQUGYQRVML-AREMUKBSSA-N	2017	US-8394826-B2	Single Stereoisomer	AR-11324 FREE BASE AR-13324 NETARSUDIL	Y
Baricitinib	Olumiant	4	Eli Lilly	ChemSpider ChEMBL PubChem DrugBank RCSB PDBe Guide to Pharmacology ZINC FDA SRS BindingDB	'3JW'	4w9x 6vn8 6wto	1	0	371.1	1.1	120.6	7	1	5	Indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs as monotherapy or in combination with methotrexate.	JAK1 JAK2	Tyr	CCS(=O)(=O)N1CC(C1)(CC#N)n2cc(cn2)c3c4cc[nH]c4ncn3	XUZMWHLSFXCVMG-UHFFFAOYSA-N	2017	US-8158616-B2	Achiral Molecule	BARICITINIB BARICITINIB PHOSPHATE BARICITINIB PHOSPHATE SALT INCB-028050 INCB-28050 INCB028050 LY-3009104 LY3009104 OLUMIANT	Y